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Objectives:  Previous studies in our laboratory have identified the antimicrobial 
proteins Human Neutrophil Protein 1 – 3 (HNP1-3), Myeloid Related Protein 8 
(S100A8/MRP8) and LL-37 as putative periodontal salivary biomarkers.  The aims 
of the studies reported in this thesis were to investigate the diagnostic and 
prognostic potential of these markers, together with Matrix Metalloproteinase- 8 
(MMP-8), serum markers C - reactive protein (CRP) and Interleukin-6 (IL-6), on 
the initial outcome of nonsurgical periodontal treatment.  
Material & Methods:  We carried out a cross sectional study which aimed to verify 
and establish a diagnostic threshold for a group of salivary biomarkers (MMP-8, 
HNP1-3, S100A8 and LL-37) and to test the validity of the diagnostic utility of these 
biomarkers. A total of 133 unstimulated saliva samples (46 with chronic 
periodontitis, 38 with aggressive periodontitis and 49 with gingivitis) were 
analysed by ELISA.  In addition multiple markers were combined to give a single 
combined cut off point by normalising each biomarker to percentage of cut-off 
point value, (such that x + y = combined cut off point).  These pre-determined cut-
off points were applied to salivary AMPs levels in an independent cohort originally 
collected to investigate the effects of diabetes on periodontitis. 
To investigate prognostic potential a total of 66 participants were recruited to a 
longitudinal intervention study of patients with moderate–severe Chronic 
Periodontitis.   53 subjects completed the protocol and were included in the final 
analysis. Subjects (28 male, 25 female) age range (23-65 years) with were 
recruited, with 14 smokers and 3 with type II diabetes, and saliva and serum 
samples were collected prior to periodontal examination.  Patients were then given 
a course of non-surgical periodontal therapy over 2 visits.  8-10 weeks post-
operatively saliva/serum sampling and clinical examination were repeated. 
Salivary MMP-8, S100A8 and HNP1-3 concentrations were all determined by 
ELISAs. In addition we measured serum levels of CRP and Interleukin 6. 
Results: In the cross-sectional study the HNP1-3 and S100A8 could differentiate 
between gingivitis and chronic periodontitis with high specificity (around 90%) and 
around 75% sensitivity compared to MMP-8 which was able to discriminate 
between gingivitis and periodontitis (chronic and aggressive) with both high   
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specificity and sensitivity.  LL37 showed no significant diagnostic potential. Within 
the independent cohort the application of pre-determined thresholds, either 
individual or combined cut-offs, were able to detect periodontitis with specificity of 
between 75 – 85 % but with very low sensitivity.  In addition diabetic status was 
found to result in significantly increased MMP-8 and S100A8 concentrations in 
subjects with periodontal disease. 
In the intervention study, treatment resulted in reductions in the mean: a) number 
of deep sites (>4mm) (33.57 ± 20.75 vs 18.51 ± 13.87; mean ± SD, p<0.0001); b) 
probing pocket depths (5.92 ± 0.47 mm vs 4.74 ± 0.76 mm, p<0.0001); c) bleeding 
index (0.32 ± 0.20 vs 0.21 ± 0.16, p<0.0001); d) plaque index (0.46 ± 0.20 vs 0.37 
± 0.18, p=0.0003). Only the mean concentrations of MMP-8 and S100A8 showed 
significant reductions post-treatment (MMP-8: 355.4 ± 319.9 ng/ml vs 216.6 ± 
217.2 ng/ml, p<0.0001), (S100A8: 1182 ± 1095 ng/ml vs 693.9 ± 719.6 ng/ml, 
p=0.0007).   Only the change in concentrations of MMP-8 were strongly 
associated with magnitude of treatment response (MMP-8: r2= 0.1, p=0.02). In 
addition, the baseline levels of MMP-8 & S100A8 were also associated with 
treatment response (MMP-8: r2= 0.1, p=0.03; S100A8: r2=0.1, p=0.02). Overall, 
there were 13 out of 53 participants who did not respond to the treatment (24.5% 
of cases).  MMP-8 baseline concentrations were significantly higher in responders 
(419.3 ± 343.1 ng/ml) than non-responders (158.8 ± 73.3 ng/ml) (p=0.009).  MMP-
8 concentrations at baseline that were above the cut-off (<182.8 ng/ml) predicted 
a good response to periodontal treatment with 77% sensitivity and 70% specificity.   
There was no effect of the single round of non-surgical periodontal treatment on 
the levels of systemic markers CRP & IL-6, and also there was no correlation 
between local and systemic markers. 
Conclusion: These results of both studies suggest that MMP-8, HNP1-3 and 
S100A8 may be useful to identify cases of periodontitis with good specificity and 
moderate sensitivity and may give superior results when combined.  In addition 
the salivary MMP-8 and S100A8 showed promising periodontal prognostic ability 
to detect the likelihood of a good response to treatment, with MMP-8 showed the 
best results with moderate sensitivity and specificity. However, further validation 
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1. Literature Review 
 
1.1 Introduction 
Periodontal disease is a chronic, site-specific, cyclic disease of multi-factorial 
aetiology. The disease is a result of imbalance between pro-inflammatory and 
anti-inflammatory signals in response to the accumulation of dental plaque on the 
tooth surface adjacent to the gingival margin. In common with many other chronic 
diseases, periodontitis is characterised by periods of active tissue destruction and 
quiescence.   
Traditionally, both diagnosis and assessment of prognosis of periodontal disease 
are based on clinical measures including probing pocket depth (PPD), clinical 
attachment loss (CAL), bleeding on probing (BOP), and radiographic assessment. 
However, these measures are of limited use for disease classification, assessing 
current disease activity, or predicting disease progression. Therefore, there is 
increasing interest in using additional diagnostic/prognostic markers in recent 
years.  
Generally, there are three ways that have been used to assess damage to the 
periodontal tissues clinically: detection of bone loss radiographically, 
measurement of clinical attachment loss, and the visual detection of any signs of 
tissue destruction (Armitage, 1996). Most of the criteria that are used to assign 
either diagnosis or prognosis of periodontal disease are tooth-related rather than 
subject-related. Therefore, it would be useful to look for markers at the patient 
level that could help in monitoring health status, disease onset, treatment 
response and outcome.  
In addition, it can still be a big challenge for the clinician to identify and treat sites 
and patients that do not respond as expected to periodontal therapy provided. 
Therefore, this PhD project aims to investigate potential biomarkers that might 
predict these different outcomes to periodontal therapy on a patient level, through 
longitudinal study of the changes in biomarkers before and after non-surgical 
periodontal treatment, and the relationship of these measures to clinical outcomes 
of treatment.   
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1.1.1 Classification and Diagnosis of Periodontal Diseases 
Plaque-induced periodontal diseases have traditionally been categorised as either 
gingivitis or periodontitis. Both plaque-induced gingivitis and periodontitis are by 
far the most frequent of all forms of diseases that may affect the periodontal 
tissues. 
The current classification system of periodontal diseases was developed in 1999 
at the International Workshop for a Classification of Periodontal Disease and 
Conditions (Armitage, 1999), in which periodontal diseases are classified into 




* Can occur on a periodontium with no attachment loss or on a periodontium with 
attachment loss that is not progressing. 
**CAL= Clinical Attachment Loss 
Table 1-1:Abbreviated version of the 1999 Classification of Periodontal Diseases 
and Conditions (Armitage, 1999). 
 
  
 Periodontal Disease 
Category 
Descriptive Criteria 
I Gingival Diseases a. Dental plaque-induced gingival 
diseases* 
b. Non-plaque-induced gingival 
lesions 
II Chronic Periodontitis a. Localized(≤30% of sites involved) 
b. Generalized(>30% of sites 
involved) 
 Slight: 1-2mm CAL** 
 Moderate: 3-4mm CAL 
 Severe: ≥5mm CAL 
III Aggressive Periodontitis a. Localized(≤30% of sites involved) 
b. Generalized(>30% of sites 
involved) 
 Slight: 1-2mm CAL 
 Moderate: 3-4mm CAL 
 Severe: ≥5mm CAL 
Usually patients below 35 years of age 
are affected 
 
IV Periodontitis as a 
Manifestation of Systemic 
Disease  
a. Associated with haematological 
disorders 
b. Associated with genetic disorders 
c. Not otherwise specified 
V Necrotizing Periodontal 
Diseases 
a. Necrotizing ulcerative gingivitis 
b. Necrotizing ulcerative 
periodontitis 
VI Abscesses of the 
Periodontium 
a. Gingival abscesses 
b. Periodontal abscesses 
c. Pericoronal abscesses 
VII Periodontitis Associated 
with Endodontic Lesions  
a. Combined periodontic-endodontic 
lesions 
VIII Developmental or Acquired 
Deformities and Conditions 
a. Localized tooth-related factors 
that modify or predispose plaque-
induced gingival 
diseases/periodontitis 
b. Mucogingival deformities and 
conditions around teeth 
c. Mucogingival deformities and 
conditions on edentulous ridges 




Gingivitis is a reversible inflammation of the gingival tissue without loss of 
attachment or alveolar bone. It can also occur in a reduced but stable 
periodontium (Highfield, 2009). Usually it represents the body’s reaction toward 
exposure of the gingival tissues to bacterial plaque (Mariotti, 1999). Classic 
studies of experimental gingivitis have demonstrated that clinical gingivitis 
develops within 21 days of ceasing oral hygiene practices and that gingival health 
is restored when these oral hygiene measures reinstituted (Lőe et al., 1967; 
Theilade et al., 1966). Interestingly, the natural history of gingivitis frequently does 
not result in progression to periodontitis (Lindhe et al., 1975). 
 
Chronic periodontitis  
(ChP) is a chronic inflammatory condition of the tooth-supporting tissues, which is 
characterised by apical migration of epithelial attachment along with alveolar bone 
destruction and loss of marginal periodontal ligament. It is cyclical in nature with 
long periods of quiescence interspersed with shorter periods of destruction  
(Socransky et al., 1984). 
The main characteristics of chronic periodontitis, according to the 1999 
classification of periodontal conditions (Armitage, 2004b) are : 
 Prevalent in adults but may occur in children. 
 The amount of tissue destruction is related to the presence of local factors 
 Subgingival calculus present at diseased sites. 
 Usually has slow to moderate rate of progression. 
 Further tissue destruction may occur if the diseased sites are left without 
treatment 
The severity of this periodontal disease may vary from one patient to another and 






Aggressive periodontitis (AgP) comprises a group of uncommon forms of 
periodontitis that tend to start at an early age and may aggregate in families.  
The common features of AgP are (Lang et al., 1999): 
 The patients are clinically healthy (Except for the presence of 
periodontitis). 
 Rapid attachment loss and bone destruction. 
 Familial aggregation. 
There are secondary features which are not present in all AgP cases (Lang et al., 
1999): 
 The amount of dental plaque is inconsistent with the severity of periodontal 
tissue destruction. 
 High proportion of Aggregatibacter actinomycetemcomitans (A.a), and in 
some Far East populations, Porphyromonas gingivalis (P.g). 
 Phagocyte abnormalities. 
 Hyper-responsive macrophage phenotype. 
 Attachment and alveolar bone loss progression may be self-arresting. 












Criteria Localised AgP Generalised AgP 
Onset Circumpubertal Usually affect 
individuals under 30 
years of age, but can 
affect older 
Serum antibody 
response to infecting 
agent 
Robust Poor 
Distribution  1st molar/incisor with 
interproximal attachment 
loss on at least 2 
permanent teeth 
(including a 1st molar) & 
not more than 2 teeth 




affecting at least 3 
permanent teeth other 
than 1st molars & 
incisors 
 
Table 1-2:showing comparison between the two forms of Aggressive Periodontitis  
(Lang et al., 1999; Tonetti and Mombelli, 2003). 
 
 
Differentiating AgP from ChP can be challenging clinically in some cases. 
However, the main differences are the rate of progression, the pattern of alveolar 
bone destruction, the amount of local factors including plaque and the age of onset 
or detection (Armitage, 1996; Armitage et al., 2010; Lang et al., 1999). Despite all 
the effort and time that has been invested to classify and diagnose periodontal 
disease, there is still no perfect classification that can sharply distinguish between 







1.1.2 Case definitions for periodontitis 
 
Currently there is a lack of uniformity in the definition of periodontitis for the 
purposes of epidemiological and other research studies and specifically there is 
no universal consensus to define a case of chronic or aggressive periodontitis.  
The adoption of universal case definitions for periodontal disease is of great 
importance in the research field. A wide range of different case definitions for 
periodontitis have been described and used in different studies, resulting in 
considerable confusion and difficulty in comparing studies directly. For instance, 
the descriptions of disease prevalence in epidemiological studies need an obvious 
and a clear disease definition, which can easily applied to the population cohort. 
Due to the fact that the criteria used to identify periodontal disease tend to be 
continuous variables (e.g. PPD & CAL) as well as the disease is site specific, this 
case definition is preferred to be dichotomised.  
The use of different case definitions has a great impact on the description of 
prevalence, severity and extent of periodontal disease. PPD and CAL are the most 
commonly used clinical parameters to measure the presence, distribution and 
severity of periodontal disease. Therefore, these continuous variables require a 
clear threshold in order to establish periodontal disease. Although CAL is a robust 
measure of the severity of periodontal disease, loss of attachment can occur 
without presence of periodontitis like in case of overhang restorations (Page and 
Eke, 2007). More recently, increasingly the case definitions described below have 
attracted some consensus for use in future studies where these definitions include 
both PPD and CAL in order to capture a true case of periodontitis. 
The Centre for Disease Control and prevention/ American Academy of 
Periodontology (CDC/AAP) has suggested the following criteria for a case with 
moderate or severe chronic periodontitis (Page and Eke, 2007): 
a) Moderate Periodontitis: Patients with two or more interproximal sites with 
clinical attachment loss of ≥4mm occurring at two or more different teeth 
OR Two or more interproximal sites with a probing depth of ≥5mm, not on 
the same tooth. 
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b) Severe Periodontitis: Patients with two or more interproximal sites with 
clinical attachment loss of ≥6mm, not on the same tooth, and the presence 
of one or more interproximal sites with a probing depth of ≥5mm. 
Demmer and Papapanou have discussed the difficulties of clinical diagnosis of 
aggressive periodontitis using the published features of this condition.  They have 
suggested the following criteria in order to diagnose a patient with Aggressive 
Periodontitis for research purposes (Demmer and Papapanou, 2010) which they 
base on the suggestion that this severity of destruction would not be 
commensurate with the amount of plaque present irrespective of plaque control: 
a) In patients ≤25 years of age, the presence of two or more interproximal, 
nonadjacent sites with attachment loss of ≥4 mm occurring at a minimum 
of two different teeth and accompanied by bleeding on probing, will signify 
aggressive periodontitis. 
b) In individuals between 26 and 35 years of age, a diagnosis of aggressive 
periodontitis will require the presence of two or more interproximal, 
nonadjacent sites with attachment loss of ≥6 mm occurring at a minimum 
















1.1.3 Treatment of Periodontal Diseases 
 
The major objectives of periodontal therapy are the control of periodontal 
infections and the maintenance of functional teeth for a lifetime. In general, there 
is a consistent chronological order to the management of plaque associated 
periodontal disease.  
Mechanical non-surgical periodontal therapy, which includes oral hygiene 
instruction, supragingival scaling & root surface debridement, is considered to be 
highly effective for the treatment of periodontitis (Badersten et al., 1985; Hill et al., 
1981; Lindhe et al., 1982; Ramfjord et al., 1987). Despite the generally good 
response to this therapy, studies have shown variations in treatment responses 
between patients and that some patients and sites did not respond to therapy 
(Claffey et al., 1996; Egelberg and Claffey, 1994; Hirschfeld and Wasserman, 
1978). 
Most of these studies have been carried out on patients with chronic periodontitis. 
The management of aggressive periodontitis may be more challenging as many 
studies recommend the use of antimicrobials as an adjunctive to the mechanical 
therapy (Haffajee et al., 2003; Herrera et al., 2002; Hung and Douglass, 2002; 
Kamma and Baehni, 2003; Sigusch et al., 2001). However, the evidence for the 
use of adjunctive antimicrobials is still equivocal. For example in another study for 
the treatment of generalised aggressive periodontitis, the use of mechanical 
debridement alone showed 54% reduction in pocket depth, whereas the additional 
use of the combination of amoxicillin and metronidazole increased this figure to 
74% (Guerrero et al., 2005). 
While the merits of non-surgical therapy are not in dispute the decision to proceed 
to surgical therapy is not always straightforward. In a study where patients were 
treated by non-surgical and surgical techniques and monitored over 5 years, they 
showed that both modalities were effective in establishing clinically healthy gingiva 
and preventing further attachment loss (Lindhe et al., 1982). They suggested in a 
later study that the critical determinant was not the technique but the quality of the 





Eaton and co- workers demonstrated that root planing under direct vision at the 
time of surgery was more effective than blind instrumentation in removing 
subgingival deposits (Eaton et al., 1985). However, in no instance was any root 
surface found to be completely free of deposits. On the other hand, performing 
periodontal surgery on plaque-infected dentitions led to recurrence of the disease 
including significant attachment loss (Nyman et al., 1977). However, Pihlstrom 
and co-workers reviewed the literature and concluded that both surgical and non-
surgical therapy resulted in probing pocket depth reduction with neither procedure 
being uniformly superior. In addition, tooth retention appeared to be more related 
to susceptibility or case type than the method of therapy performed (Pihlstrom et 
al., 1983). 
Irrespective of the type of treatment provided, a site which is responsive to 
treatment will show resolution of gingival inflammation (no redness, no swelling, 
and no bleeding on probing), reduction of pocket depths, and gain of clinical 
attachment level.  However these outcomes may be considered as surrogate 
endpoints of treatment, and tooth survival/loss is a” true” end point of periodontal 
treatment outcome. There are not many studies that have looked at the 
prevalence of tooth loss both during active periodontal therapy and during long-
term maintenance. Those that have report an overall percentage of tooth loss of 
7.8% (Konig et al., 2002), 8.3% (Carnevale et al., 2007) and 8.8% (Tonetti et al., 
2000). Even teeth with advanced periodontal disease can be kept healthy in the 
long term if a strict periodontal maintenance is applied. A 14 year longitudinal 
study of treating and maintaining patients with advanced periodontal diseases 




Interestingly, a systematic review concerned with tooth loss during long-term 
periodontal maintenance (≥5 years) concluded that long-term periodontal 
maintenance maintained periodontal health and prevented tooth loss in most 
patients. These findings led to low rates of tooth loss due to periodontal reasons 
(Chambrone et al., 2010). This includes the finding of a 30-year maintenance 
study by Axelsson and co-workers that showed the prevalence of periodontal 
disease progression and tooth loss was very small (Axelsson et al., 2004).  This 
was particularly the case when patients were under a strict maintenance 
programme (Checchi et al., 2002).  In addition, the periodontal stability of patients 
maintained by a specialist was much better than ones maintained by general 
dentist (Eickholz et al., 2008; Fardal, 2006).  
Overall, treatment failures tended to cluster in a small cohort of the treated 
patients, and partially associated with periodontal maintenance and with the 
adverse effects of smoking.  These observations also suggest the involvement of 
other factors may also affect treatment outcomes, and these might include other 
recognised periodontal risk factors such as genetics, systemic health, and type of 















1.1.4 Prognostic Factors of Periodontal Disease 
 
Prognosis is the prediction of the course, duration and outcome of a disease 
based on the pathogenesis and presence of risk factors for the disease. Usually 
prognosis is estimated after establishing diagnosis and before planning treatment. 
Development of an accurate prognosis is an essential part of treatment planning 
in periodontal clinics. Different practitioners may assign varying prognoses for the 
same tooth, as there are no well-established universal guidelines for assignment 
of periodontal prognosis. Dental practitioners usually rely on the clinical 
parameters to predict the long term outcome of the provided periodontal therapy. 
The most used measures are Probing Pocket Depth (PPD), Gingival Recession & 
Attachment Level (AL). Other clinical parameters have also been used to assess 
the prognosis such as bleeding on probing (BoP), presence of plaque, furcation 
involvements and the site of the lesion (Persson, 2005). However, previous 
studies suggest that these clinical parameters are relatively poor prognostic 
factors of future disease progression especially in the short term (Claffey, 1991; 
Claffey etal.,1990; Haffajee et al.,1988).  
 Although BoP is an essential criterion for the diagnosis of gingivitis and an 
indicator of periodontal disease activity, it is limited as a periodontal prognostic 
indicator (Armitage, 1996; Lang et al., 1986). Furthermore, Claffey and Egelberg 
concluded in their study that residual probing depth was moderately predictive of 
further disease progression, whereas persisting bleeding on probing was not 
(Claffey and Egelberg, 1995). 
The traditional paradigm that is used to assign teeth prognoses is based on an 
outdated model of disease progression that assumes all subjects are equally 
susceptible to gum disease and that all plaque is the same. Under this paradigm 
the most commonly used clinical parameters in assigning prognosis can be 
divided into two categories (McGuire and Nunn, 1996) Table 1-3: 






Individual tooth prognosis  Overall prognosis 
 Percentage bone loss Age 
Probing depth Medical status (smoker &/or diabetic) 
Distribution and type of bone loss Rate of progression 
Presence and severity of furcation Patient cooperation 
Mobility Economic considerations 
Crown/Root ratio Knowledge and ability of dentist 
Root form Family history of periodontal diseases 
(mother, father, siblings) 
Caries/Pulpal involvement Oral hygiene (good, fair, poor) 
Tooth position and occlusal 
relationship 
Maintenance interval  
Fixed or removable abutment Para-functional habits (± bite-guard) 
 
Table 1-3:The commonly taught clinical factors used in assigning prognosis 
(McGuire and Nunn, 1996). 
 
One study made a comparison between prognosis and actual outcome in order 
to determine if the widely used clinical parameters are effective in assigning an 
accurate individual tooth prognosis (McGuire and Nunn, 1996); the results 
indicate that teeth with good prognosis generally remained good. While in teeth 
with less than good prognosis the overall accuracy in assigning prognosis was 
only 43% at 5 years and 35% at 8 years. Furthermore, in a later study (McGuire 
and Nunn, 1999) they concluded that heavy smoking and positive IL-1 genotype 
are significantly associated with tooth loss. 
As periodontal disease is site-specific, it may be difficult to assess accurately the 
overall treatment outcome from different sites within the same individual. In a 
study by D’Aiuto and co-workers of prognostic factors, the authors suggested that 
site-specific factors were the major determinants of initial outcome of treatment in 
severe periodontitis (D'Aiuto et al., 2005c). However, this would tend to be 
contradicted by the widely noted observation that treatment failures (i.e. tooth 





In general, systemic or patient level prognostic factors need to be considered, 
such as smoking, diabetes or genetic factors, as well as local factors such as 
furcation or mobility. Regarding the relationship between the commonly taught 
clinical parameters and tooth loss rate, some clinical factors, such as satisfactory 
crown/root ratio, heavy smoking, mobility or furcation involvement, contributed 
significantly to predict the tooth loss rate, while other factors, such as patient age 
or root form, showed a weak relationship to the probability of tooth loss (Nunn et 
al., 2012). 
In a longitudinal prospective study over 30 years of professional periodontal 
maintenance of patients with periodontal disease, the incidence of caries, 
periodontal disease progression and tooth loss was very low (Axelsson et al., 
2004). In addition, in a later study Eickholz and co-workers  identified that irregular 
participation in supportive periodontal treatment was the strongest influence 
associated with tooth loss over other factors like age, sex, baseline diagnosis, IL-
1 polymorphism and smoking (Eickholz et al., 2008).  
Both clinical and certain immunological and microbiological parameters have also 
been evaluated for predicting change in clinical status and tooth loss (Machtei et 
al., 1997; Machtei et al., 1999). Mean probing depth, mean attachment loss, 
crestal bone height, baseline smoking status, and cotinine level were all 
associated with bone and attachment loss over time. The presence of Bacteroides 
forsythus, Prevotella intermedia and Porphyromonas gingivalis was linked to 
future periodontal breakdown (Machtei et al., 1997). Loss of crestal bone height, 
baseline attachment loss, and different systemic conditions were associated with 
increased tooth loss over time, while the presence of B.forsythus doubled the risk 
of tooth loss over time (Machtei et al., 1999). 
Therefore, in view of the difficulties in accurately assessing prognosis, there is 
increased interest in improving the way of assessing the individual patient 







1.1.5 Biomarkers and Periodontal Diseases 
 
Periodontal disease is irreversible, multifactorial and cumulative in nature and 
both dental plaque and host factors are involved in determining its progression.  
Therefore, there is no single way either clinically or by laboratory testing that can 
describe the true pathogenesis of periodontal disease. This leads to the thinking 
of other novel ways such as identifying and detecting host and bacteria-derived 
proteins as surrogate periodontal biomarkers. These proteins (markers) can be 
obtained from sampling saliva, serum, GCF, sub-gingival plaque and gingival 
tissue. 
The current diagnosis of periodontal diseases is based on visual and radiographic 
examinations (which has a lot of subjectivity), which often indicate only the 
consequences of past diseases. Early prediction of risk and accurate diagnosis of 
current disease activity are needed for effective prevention and treatment. That is 
why periodontists would greatly value an objective diagnostic tool that can provide 
reliable information to assess the existence, severity and outcome of disease 
(Buduneli and Kinane, 2011; Sexton et al., 2011). 
The term “biological marker” has been defined as “an indicator that signals events 
in biological systems or samples, and it is generally taken to be any biochemical, 
genetic or immunologic indicator that can be measured in a biological specimen” 
(Hulka and Wilcosky, 1988; Schulte, 1989).The biomarker can be extrinsic or 
intrinsic, diagnostic or prognostic, and can be subdivided into many categories.  
In periodontology there is thus a need for a marker that is able to distinguish 
accurately between different disease categories, ideally with both high sensitivity 
and specificity. i.e. a test with great diagnostic potential. In this context sensitivity 
is defined as the ability of a diagnostic test to identify the disease when it truly 
exists. Specificity is the probability of a diagnostic test being negative when the 
disease is truly absent. Interestingly, demonstration that average concentrations 
of biomarker are different between two groups (disease categories) does not 
always indicate that this marker has a true diagnostic or prognostic utility. 
Oral fluids usually contain large amounts of serum proteins, inflammatory 




et al., 2007; Sorsa et al., 2004a; Uitto et al., 2003), suggesting they may be a very 
useful and accessible source of biomarkers for a wide range of conditions. In 
particular, saliva and gingival crevicular fluid (GCF) have been investigated 
extensively as these oral fluids may reflect the disease status of the oral cavity 
(Kaufman and Lamster, 2002; Lamster and Ahlo, 2007; Taba et al., 2005). 
The identification of biological markers that are associated with periodontal 
disease activity might help in the development of new periodontal therapies, in 
detection and monitoring of disease, in stratifying patients for diagnostic, 
prognostic and treatment planning purposes, and as surrogate measures of 
periodontal disease in field studies of periodontal disease where full periodontal 
examination might be impractical.   
Although a wide range of host- and pathogen-derived markers have been 
investigated in these body fluids, there is currently no one single biomarker with 
sufficient power to confidently detect or predict the presence of periodontal 
disease (Kaufman and Lamster, 2000; Ozmeric, 2004). Broadly, potential 
periodontal disease markers can be classified into four main groups (Chapple, 
1997) that indicate: 
1. Presence of putative periodontal pathogens. 
2. Gingival and periodontal inflammation. 
3. Host`s immune response. 
4.  Host tissue destruction. 
Due to the complex nature of periodontal disease, it is more likely that multiple, 
and not individual, biomarkers together can discriminate between health and 
disease or disease onset and progression, enhance the outcome disease 
prognosis, prioritise patients according to their treatment need and identify the 
ones who will respond well to the offered treatment. 
In addition, consideration has to be made as to the source fluid of the biomarker, 




Gingival Crevicular Fluid (GCF) 
GCF is a serum transudate or inflammatory exudate that seeps into gingival 
crevices or periodontal pockets around teeth with inflamed gingivae, it is 
composed of serum and locally generated materials such as tissue breakdown 
products, inflammatory mediators, and antibodies directed against dental plaque 
bacteria (Armitage, 2004a). 
GCF acts as a medium for the transport of bacterial products into and host derived 
products out of the periodontal environment. The interest in the diagnostic 
potential of GCF has increased since the suggestion by Brill that analysis of the 
GCF might be a way to evaluate quantitatively the inflammatory status of gingival 
and periodontal tissues (Brill, 1962). GCF has been suggested by some 
researchers to be the most promising medium for the collection of diagnostic 
information, due to its location adjacent to periodontal tissue where periodontal 
disease starts (Chapple, 1997). 
Bacterial antigens trigger monocytes to release inflammatory mediators including 
PGE2, IL-1, IL-6, IL-8, TNF and collagenase that increase local destruction of the 
connective tissues.  Therefore, levels of these monocytic inflammatory mediators 
may well represent the site level markers of disease activity. In addition, elevated 
levels of GCF neutrophil mediators including neutrophil elastase, β-glucoronidase 
and LTB4 may reflect acute episodes of localised tissue destruction (Champagne 
et al., 2003). Over 65 GCF markers have been examined as possible markers for 
periodontal disease progression (Armitage, 2004a; Ozmeric, 2004)  
Table 1-4. 
In a review by Loos and Tjoa, the authors concluded that there was no single or 
combination of GCF markers available to use in order to distinguish between 
chronic or aggressive periodontitis, as well as to predict the outcome of 
periodontal treatment (Loos and Tjoa, 2005). Therefore, well-controlled 
longitudinal clinical trials are needed in order to establish reliable biomarkers for 
periodontal disease as most published work about biomarkers and periodontal 





Enzymes Proteins Igs Cytokines Others 
Lysozyme  Lactoferrin IgA  VEGF  PAF  
MMP-8 
(collagenase 2)  
cystatinsC,S IgG IL-1β leukotriene B4 
MMP-2  Neopterin IgM TNF-α thromboxane B2 
MMP-9  β-NAH  IgE  IL-2  hydroxyproline 
MMP-13 
(collagenase-3)  
TIMP   INF-α lipoxin A  
Neutral protease  osteopontin  IL-10  keratin  
Dipeptidylpeptidase calprotectin  RANTES  substance P  
Alkaline 
phosphatase  





 IL-1ra glucose  
Myeloperoxidase  Endothelin  IL-4  ICAM-1  
Creatine kinase  proteoglycan   IL-6  methylglyoxal 
Lactate 
dehydrogenase  
thrombomodulin  TGF-β lactic acid  
Elastase transferrin   HGF  propionic acid  
β-Glucuronidase C-reactive 
protein  
 EGF  butyric acid  
Cathepsin G,D, B  α-2-
macroglobulin  
  phylloquinone 
Plasminogen  α-1-antitrypsin    Volatile sulphur 
compounds 
Gingipain Osteocalcin   glutathione  
 osteonectin   hydroxylysylpyridinoline 
 Hyaluronan    
 Fibronectin    
 ICTP     
 α-1-EPI    
 NTx    
 E-selectin    
 neurokinin-A     
 MRP-8     
 calcitonin     
 albumin     
 
Table 1-4: Possible GCF markers for periodontal disease suggested for potential 





On a practical level, salivary analysis offers significant advantages when used for 
diagnostic purposes, as it is easily collected in a non-invasive way. In addition, it 
may provide a feasible, cost-effective approach for screening a large number of 
patients (Lamster and Ahlo, 2007). Furthermore it is most likely that salivary 
biomarkers would be most suited to assessing patient-level diagnostic or 
prognostic biomarkers as it is not likely to reflect site specific differences. 
Whole  (mixed) saliva is a combination of oral fluids that originates from secretions 
of the minor and three paired major salivary glands, bronchial and nasal 
secretions, serum and blood derivatives from oral wounds, bacteria and bacterial 
by-products, viruses, fungi, desquamated epithelial cells, food, cellular 
components and GCF (Kaufman and Lamster, 2000; Mandel and Wotman, 1975; 
Sreebny, 1988) Figure 1-1. Therefore, whole saliva represents a complex balance 
between local and systemic sources, and biomarker analysis of such a pooled 
sample might provide an overall periodontal disease assessment rather than site-
specific GCF analysis. This is why saliva has great potential in the diagnosis of 
oral and systemic conditions (Good et al., 2007; Lee et al., 2009; Malamud, 2011).  
It has been shown that out of 2290 identified WS proteins, there are 1163 specific 
for WS which are neither found in plasma nor in glandular saliva (Loo et al., 2010) 





Figure 1-1: Components of whole saliva (WS). Acknowledgement: (Kaufman and 




Figure 1-2: Venn diagram showing the overlapping protein identifications         
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As mentioned earlier, whole saliva contains more than two thousand proteins (Loo 
et al., 2010). Out of these proteins, in the study here we were particularly 
interested in four proteins as potential periodontal biomarkers, specifically Matrix 
Metalloproteinase-8 (MMP-8) and the antimicrobial peptides (AMPs) Human 
Neutrophil Peptide 1- 3 (HNP1-3), S100A8 and LL-37. The reason for choosing 
MMP-8 was due to the wealth of research indicating that MMP-8 is a promising 
biomarker for periodontal disease (Miller et al., 2006; Todorovic et al., 2006). For 
the AMPs HNP1-3, S100A8 & LL-37 results from a recent study in our laboratory 
have identified these three AMPs, using mass spectrometry techniques, as 
potential diagnostic biomarkers for periodontal disease (Mulli, 2012).  In this study 
Dr.T.Mulli was able to identify 67 proteins out of 115 in saliva and GCF using 
Surface Enhanced Laser Desorption Ionization- Time Of Flight Mass 
Spectrometry (SELDI-TOF MS) with the potential to distinguish between gingivitis 
and periodontitis. Only 3 distinct peaks on the SELDI MS (HNP1-3, LL-37& 
S100A8) were conclusively identified using Liquid Chromatography quadruple 
Mass Spectrometry (LC-MS/MS). Interestingly, these are all known antimicrobial 
peptides (AMPs) and therefore of considerable potential biological significance in 
periodontal disease.  In addition, he showed the potential diagnostic utility of these 
biomarkers, particularly HNP1-3 & S100A8. However he also found that the 
method used for saliva collection had marked effects on the concentration of some 
salivary analytes.  He used salivettes & spitting methods to collect saliva samples 
in different studies and the spitting method showed much higher concentrations 
of analytes (AMPs) than salivettes.  Because of this he was unable to validate 
specified cut-off points of AMP concentrations in a separate population of samples 










MMP-8 (Matrix Metalloproteinase-8) (Neutrophil Collagenase II)  
(Collagen Cleaving Enzyme) (Neutrophil-derived proteolytic 
enzyme): 
Proteins of the matrix metalloproteinase (MMP) family consist of approximately 25 
members that can be categorised into five main groups: Collagenase, Gelatinase, 
Stromelysins, membrane-type, and others. They are involved in the breakdown of 
collagen and extracellular matrix (ECM) in normal physiological processes, such 
as embryonic development, reproduction, and tissue remodelling, as well as in 
pathological processes, such as arthritis and metastasis (Sorsa et al., 2004). They 
may play an important role in the pathogenesis of periodontal disease, in which 
their role should not be considered as destructive factors only but which may also 
have protective or defensive roles (Sorsa et al., 2011; Sorsa et al., 2004). For 
example physiological levels of MMP-8 can perform an anti-inflammatory effect 
by processing some cytokines and chemokines (Sapna et al., 2014). Most MMPs 
are secreted as inactive proproteins which are activated when cleaved by 
extracellular proteinases. MMP activity is also regulated by Tissue Inhibitors of 
MetalloProteinases (TIMPs) that are responsible for protecting the PDL from 
degradation by MMPs in the state of health. TIMPs can play a role in MMPs 
stabilisation and transportation alongside their major role as MMPs inhibitors 
(Sorsa et al., 2006). Degradation of ECM, collagen fibres and alveolar bone might 
be triggered by the imbalance between MMPs and their inhibitors (Reynolds, 
1996). 
The gene encoding MMP-8 is called homo sapiens complex locus MMP8, and the 
enzyme encoded by this gene is stored in secondary granules within neutrophils 
and is activated by autolytic cleavage. Its function is degradation of type I and III 
collagens, which is critical for periodontal tissue destruction in periodontitis but not 
for physiological gingival tissue remodelling (Rai et al., 2008). The gene is part of 
a cluster of MMP genes which localize to chromosome 11q22.3 (NCBI website). 
It is found in specific granules in neutrophils, but is also expressed by diverse cell 
types including epithelial cells, fibroblasts, macrophages and endothelial cells 
(Van Lint and Libert, 2006). It exists in the inflammatory exudate within the gingiva 
and in oral fluids (saliva & GCF) due to the permeability of the sulcular epithelium 
(Miller et al., 2006). 
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In addition to MMP-8, there are other types of MMPs that are involved in 
periodontal tissue destruction including MMP-9, MMP-13 (Hernandez et al., 2006; 
Hernández Ríos et al., 2009), MMP-25 & MMP-26 (Emingil et al., 2006) which all 
have been suggested as potentially useful biomarkers for progression of 
periodontal disease. Also, the gelatinase group (MMP-2 & MMP-9) may 
participate in periodontal tissue destruction during periodontitis (Makela et al., 
1994), and their levels have been shown to reduce after periodontal therapy 
(Gursoy et al., 2013; Marcaccini et al., 2010). However, MMP-8 is the most studied 
MMP in relation to periodontal disease and particularly as a potential disease 
biomarker. 
In previous studies MMP-8 levels in patients with periodontal disease were an 
indicator for disease severity as well as activity (Herr et al., 2007; Romanelli et al., 
1999). A recent study by (Adina Bianca Boşca, 2012) concluded that MMP-8 may 
be a reliable diagnostic marker of periodontal disease, as it was significantly 
higher in patients with chronic periodontitis compared to healthy controls. Also, 
they showed that there was a correlation between raised levels of MMP-8 and the 
severity of periodontitis assessed clinically & histologically. Furthermore, MMP-8 
has been suggested as a potential periodontal biomarker between health and 
disease (Miller et al., 2006; Todorovic et al., 2006), as well as a prognostic marker 
of periodontal disease (Passoja et al., 2008; Ramseier et al., 2009).  
In studies investigating the relationship between Salivary and GCF MMP-8 levels 
and periodontal disease, MMP-8 levels were significantly higher in subjects with 
chronic periodontitis than subjects with gingivitis and healthy controls (Rai et al., 
2008; Xu et al., 2008). Also, it has been suggested that persistent elevation of 
GCF MMP-8 levels might be indicative of high risk to periodontal disease and poor 
response to periodontal treatment (Mäntylä et al., 2006).   Moreover, Kinane and 
co-workers in their intervention study included 20 subjects with chronic 
periodontitis, concluded that the MMP-8 GCF levels were reduced significantly 
following periodontal treatment (Kinane et al., 2003). A further treatment study 
investigated the MMP-8 plasma levels of 28 patients with periodontitis and 22 
controls and concluded that MMP-8 levels were higher in the diseased group but 
reduced significantly 3 months after non-surgical periodontal treatment 
(Marcaccini et al., 2009b).  
Mantyla and co-workers have developed a chair-side GCF MMP-8 test (Lab on 
Chip (LOC)) to differentiate periodontitis from gingivitis or healthy sites, as well as 
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to monitor treatment outcome of periodontitis. This is a potentially useful first 
MMP-based point-of-care (POC) test developed to diagnose a tissue destructive 
oral disease (Mäntylä et al., 2003). Also, Herr and co-workers have introduced a 
microfluidic assay for POC rapid quantification of salivary MMP-8 to identify 
subjects with periodontitis (Herr et al., 2007). In addition, the MMP-8 oral rinse 
sample analysis POC test could be clinically beneficial in rough screening to 
identify subjects who at risk to develop periodontitis, as well as to define the 
maintenance phase visits after active periodontal treatment (Leppilahti et al., 
2010).  
A recent study by Gursoy and co-workers concluded that MMP-8 is a strong 
biomarker candidate for detecting alveolar bone destruction, as their levels were 
higher in subjects with severe bone loss than those with slight bone loss (Gursoy 



















Antimicrobial Peptides (AMPs) 
Antimicrobial peptides are defined as peptides that are smaller than 100 amino 
acids, usually 12-50 amino acids, which act like broad-spectrum natural antibiotics 
and have the ability to kill different species/ strains of oral bacteria. In addition, 
AMPs have antiviral, antifungal and antiparasitic activities. Therefore, AMPs play 
an important role as part of the innate host defence mechanisms against microbial 
colonization both synergistically and independently (Diamond et al., 2009). Only 
45 AMPs have been identified in saliva and many of them do exist in GCF as well 
(Gorr and Abdolhosseini, 2011). Examples of these AMPs families are: defensins, 
cathelicidins and histatins. See Figure 1-3 for the summary of AMPs’ functions. 
 
 
Figure 1-3: Schematic draw showing the multifunctional properties of 
antimicrobial peptides. Acknowledgement (Pushpanathan et al., 2013).  
 
Most AMPs are cationic peptides (positively charged) and have both hydrophilic 
and hydrophobic sides. Therefore, they are attracted to the anionic (negatively 


















environments (Brogden, 2005). The most accepted hypotheses of their action are 
the disruption of microbial membrane function by forming pores using one of three 
means (Brandenburg et al., 2012) Figure 1-4: 
A. Barrel-stave: in which the peptides aggregate and penetrate the bacterial 
bilayer membrane to align the hydrophobic regions of the peptides with the 
bacterial lipid core region, and the hydrophilic peptide regions form the 
pore core. 
B.  Toroidal: in which the peptides aggregate and cause the lipid monolayer 
to bend continuously through the pore, then the water core is lined by both 
the inserted peptides and the lipid head groups. 
C. Carpet channels: in which the peptides disrupt the lipid bilayer membrane 
by aligning parallel to it and form a carpet.  
Overall, the final effect of all these means is that some monomer can pass to the 
cytoplasm and bind to the cellular DNA and RNA, causing protein synthesis 
inhibition or protein folding. In addition, increasing cell permeability and causing 
cell death (Brandenburg et al., 2012). 
  
 
Figure 1-4: Schematic draw showing the proposed AMPs mechanism of action in 
bacteria. Acknowledgement  (Brandenburg et al., 2012). 
 
Interestingly, it has been suggested that the high risk of periodontal disease in 
patients with systemic diseases might be attributed to the alteration in these 
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salivary AMPs. For example patients with diabetes reportedly have low 
concentrations of statherin and Histatin 1 & 3, and high concentrations of HNP1, 
2, 4 and S100A9 compared to healthy controls (Cabras et al., 2010). Moreover, 
Morbus Kostmann disease in humans is due to deficiency in HNP1-3 and LL-37, 
in which patients suffer from severe periodontal disease and recurrent oral 
infections (Putsep et al., 2002).  
 
HNP1-3 (Human Neutrophil Peptides) (α-defensins) 
These AMPs are three of the six different human α-defensins. Neutrophils are the 
main source of these antimicrobial peptides, where they are stored in azurophilic 
(primary) granules in a biologically active form (Ganz, 2003; Ganz et al., 1985). 
However, they can be released from other cell types including monocytes, B & T-
lymphocytes (Schneider et al., 2005). Surprisingly, the number of neutrophils is 
unrelated to the levels of HNP1-3 in patients with periodontal disease which 
emphasises the fact that HNP1-3 can be secreted from cells other than 
neutrophils, or alternatively points to complexities in the regulation of their 
production and secretion (Puklo et al., 2008). 
Alpha defensins are not completely active within the PD pockets. They have a 
wide range of antimicrobial activity as well as a stimulatory effect on fibroblast 
proliferation. Their bactericidal activity can be aborted, by proteolytic degradation 
or by the action of dermatan sulphate containing proteoglycan that is released by 
bacteria proteases (Schmidtchen et al., 2001).  
It has been previously reported that the concentration of GCF HNP1-3 is much 
higher in patients with chronic periodontitis than those with aggressive 
periodontitis and very low in healthy controls (Puklo et al., 2008). In contrast other 
studies have not shown any significant differences in the amount of α-defensins 
between subjects with healthy and diseased periodontium (Lundy et al., 2005; 
Turkoglu et al., 2010).  
As well as their potential protective effects, elevated local levels of α-defensins in 
periodontal tissues may also have destructive effects. HNP1–3, at concentrations 
of 5–8µg/ml, stimulate the proliferation of periodontal epithelial cells, and at very 
high concentrations (of 50µg/ml) induce cell-death of human oral fibroblasts 




S100A8/MRP8 (Myeloid Related Protein 8) (Calgranulin A) 
This peptide is one of the twenty members of low molecular weight calcium binding 
proteins, S100 family. It forms a dimer with S100A9/MRP14 (Calgranulin B) called 
Calprotectin, which is a crucial pro-inflammatory mediator that is highly expressed 
in inflammatory sites by neutrophils and monocytes (Kido et al., 1999; Sun et al., 
2011). It plays an important role in innate immune mechanisms as it induces 
neutrophil chemotaxis and adhesion (Sun et al., 2011), and shows antimicrobial 
activity by its zinc-chelating action (Gorr and Abdolhosseini, 2011). 
Some studies have documented that patients with diabetes, cardiovascular 
disease and prostate cancer have high levels of calprotectin (Altwegg et al., 2007; 
Bouma et al., 2004; Hermani et al., 2005).  Moreover, GCF calprotectin levels of 
patients with periodontal disease were higher in diseased sites than healthy ones 
(Kido et al., 1998; Li et al., 1998; Zhou et al., 1998). Similar results have been 
found in plasma calprotectin levels in patients with aggressive periodontitis (Sun 
et al., 2011). Therefore, these findings may provide more support to the 
association of periodontal disease with systemic disease. However in another 
study by (Haigh et al., 2010) it was concluded that S100A8 & A9 are increased 
after treatment of periodontal disease. 
 
LL-37 (Cathelicidin)  
LL-37 is the only cathelicidin-derived AMP in humans, where it can be found in 
most body fluids and shows a potent and broad spectrum antimicrobial activity 
(Nijnik and Hancock, 2009). Like α-defensins neutrophils are the most abundant, 
but not the only, source of LL-37, where it is synthesized as preproproteins and 
stored within specific (secondary) granules in an inactive form. Although saliva 
can partially inhibit the activity of LL-37, it protects the peptide from degradation 
by gingipain protease secreted by dental plaque bacteria (Gutner et al., 2009).  
LL-37 may play an important role in protecting the human periodontium from 
dental plaque bacteria, and has been reported to be especially effective against 
A.a (Gomez-Garces et al., 1994). This supports the findings of a later study by 
Puklo and co-workers that local deficiency of LL-37 can be found in severe cases 
of periodontitis (Puklo et al., 2008). On the other hand, another study found that 
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LL-37 GCF levels were significantly higher in patients with chronic periodontitis 
(Türkoǧlu et al., 2009). An interesting finding by Nagaoka and co-workers is that 
LL-37 is crucial for the efficacy of the α-defensins’ antimicrobial activity as both 
AMPs work synergistically (Nagaoka et al., 2000).    
 
Serum 
Blood is by far the most popular and accepted choice for biomarker testing 
clinically in medicine, due to the fact that blood is the circulating fluid that 
surrounds all tissue and organs and collects by-products from diseased areas. 
Periodontal disease is inflammatory in nature and can stimulate the body to 
release inflammatory cytokines such as IL-1β, IL-6 & TNF-α not only locally, but 
also systemically (Offenbacher et al., 1996). These cytokines may cause chronic 
low-grade systemic effects that involve hepatic secretion of CRP (Scannapieco, 























Figure 1-5: Theoretical mechanisms by which gingival inflammation may 
modulate systemic disease (Acknowledgement (Scannapieco, 2004)).   
 
Therefore, it has been proposed that periodontitis may play a role in the 
aetiological mechanisms of many systemic diseases via this induction of systemic 
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(eg: heart, brain…etc) 
49 
 
measure the inflammatory level of an individual and their levels are elevated in 
subjects with severe periodontitis (Loos et al., 2000); in addition these markers 
(IL-6 &CRP) are well recognised as useful biomarkers for cardiovascular diseases 
(Danesh et al., 2000; Ridker et al., 1997).  
The majority of serum-based biomarkers that have been studied in periodontal 
disease have focussed on the levels of serum antibodies to certain pathogens, 
and latterly on factors that may indicate systemic inflammation such as C-reactive 
protein (Chapple, 1997; D'Aiuto et al., 2004; Paraskevas et al., 2008). Therefore, 
in this study we were interested into two serum markers; CRP &IL-6. 
 
1.1.6 Systemic Inflammation and Biomarkers 
There has been extensive interest in recent years in the links between periodontal 
disease, systemic inflammation and a number of systemic conditions including 
CVD, diabetes, adverse pregnancy outcomes, and others such as osteoporosis, 
rheumatoid arthritis and chronic kidney disease.  Interpreting these studies which 
show a positive association of periodontal disease with risk of these systemic 




In terms of the association of CVD with PD, there is strong and consistent 
epidemiological evidence from a number of systematic reviews with meta-
analyses that both the prevalence and incidence of CVD is increased in subjects 
with periodontitis (Bahekar et al., 2007; Blaizot et al., 2009; Humphrey et al., 2008; 
Janket et al., 2003; Khader et al., 2004; Paraskevas et al., 2008; Sfyroeras et al., 
2012). However, most of the included studies in these meta-analyses have been 
criticised for either lack of uniform definition of periodontitis, small sample size, or 
incomplete adjustment for all Framingham risk factors especially tobacco 
consumption. In addition many studies have shown an association between PD 
and biomarkers of CVD such as elevated CRP levels (D'Aiuto et al., 2004; Liu et 
al., 2010), endothelial dysfunction of peripheral blood vessels (Mercanoglu et al., 
2004; Seinost et al., 2005; Tonetti et al., 2007) and thickness of carotid intima-
media (Piconi et al., 2009).  However, it was concluded in the joint workshop of   
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EFP/AAP on periodontitis and systemic disease that although the association 
between periodontitis and Atherosclerotic Cardio-Vascular Disease (ACVD) is 
confirmed, we still need well-designed intervention trials to investigate the effect 
of periodontal treatment on the prevention of ACVD (Tonetti and Dyke, 2013).  
 
Diabetes Mellitus 
There is a wealth of epidemiological and biological evidence demonstrating that 
diabetes mellitus (DM) is an established risk factor for periodontitis, that diabetics 
with poor glycaemic control are at greater risk of having progressive and severe 
periodontitis than those with well controlled diabetes (Chávarry et al., 2009; 
Emrich et al., 1991; Khader et al., 2006; Salvi et al., 2008; Taylor et al., 1996; Tsai 
et al., 2002), and the risk for periodontitis in diabetics is increased by up to 
threefold compared to non-diabetics (Mealey and Ocampo, 2007). Noticeably, 
most of the research has focused on type II DM due to the fact that both PD and 
DM historically tend to develop in subjects in their forties and fifties. However, 
patients with type I DM are also at risk of PD.  
In addition, there is considerable discussion about whether PD may increase the 
risk of DM, and, following on from that if treatment of PD may improve glycaemic 
control in DM (Taylor, 2001).    
Serum levels of the pro-inflammatory cytokine TNF-α, which is closely linked to 
insulin resistance (Type II diabetes), are elevated in subjects with severe 
periodontitis, which has suggested that treating periodontal disease in type II 
diabetic subjects could restore insulin sensitivity resulting in improved glycaemic 
control (Engebretson et al., 2007; Iwamoto et al., 2001) by reduction of both local 
and systemic inflammation (Mealey and Rose, 2008).  
Many interventional clinical studies of diabetic subjects with severe periodontitis 
have shown significant improvements in their glycaemic control after standard 
periodontal therapy alone (Kıran et al., 2005; Rodrigues et al., 2003; Stewart et 
al., 2001) or with adjunctive antimicrobials (Grossi and Genco, 1998; Grossi et al., 
1997; Grossi et al., 1996).  However, other similar studies have not found this 
significant effect of periodontal therapy on glycaemic control (Engebretson et al., 
2013; Janket et al., 2005; Jones et al., 2007).   
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Meta-analyses have concluded that treating periodontal disease in type II diabetic 
subjects could improve the glycaemic control (Darré et al., 2008), for at least three 
months (Teeuw et al., 2010). However, other reviews have criticised that these 
interventional studies were few and most of them were lacking the power to detect 
the significant effect of treating periodontitis on glycaemic control (Engebretson 
and Kocher, 2013; Lalla and Papapanou, 2011; Simpson et al., 2010).  
In addition, in a recent systematic review of epidemiological non-interventional 
evidence of effects of PD on diabetes incidence, control and complication, by 
Borgnakke and co-workers, they concluded that the current evidence is scarce 
(Borgnakke et al., 2013).  
Therefore, the joint workshop of EFP/AAP consensus report on periodontitis and 
systemic diseases reported that further research is needed to clarify these 
relationships and prospective, larger, controlled trials are needed in order to 
establish that treating periodontitis could improve the glycaemic control of subjects 
with diabetes (Chapple and Genco, 2013).  
 
Obstetric Outcomes 
There is also extensive research into the potential association between PD and 
adverse pregnancy outcomes like preterm birth, pre-eclampsia and low birth 
weight (Boggess et al., 2003; Chaparro et al., 2012; López, 2008; Offenbacher et 
al., 2006; Xiong et al., 2006). However, it is still unclear how periodontal disease 
can adversely affect these outcomes.  Interestingly, some studies suggested that 
treating periodontitis during pregnancy could reduce the risk of preterm birth 
(Jeffcoat et al., 2003; López et al., 2002). Even more, a recent systematic review 
has shown that the non-surgical periodontal treatment of pregnant women (with 
high risk of preterm birth only) with periodontitis significantly reduce the preterm 
birth risk (Kim et al., 2012). On the other hand, many recent systematic reviews of 
large and high quality randomised clinical trials have concluded that maternal 
periodontal disease treatment, delivered early in pregnancy, has no effect on the 
adverse pregnancy outcomes (Chambrone et al., 2011; Michalowicz et al., 2013). 
Therefore, the EFP/AAP joint workshop of periodontitis and systemic disease 
advised that further research is needed to better understanding of the   
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pathophysiology and risk profile that behind this link, to define the best time and 
type of treatment intervention, and to identify the subgroup of pregnant women 
who will benefit from such an intervention (Sanz and Kornman, 2013).  
Based on these associations, periodontal infections might be considered a 
significant risk factor for some systemic diseases, and in turn control of periodontal 
diseases might be of great importance in the prevention and management of 
several systemic diseases although clear evidence of this remains inconclusive.  
However there is now clear evidence that periodontal disease can cause systemic 
inflammation and it has been postulated that there might be a mechanistic link 
between these conditions.  In particular the relationship between periodontal 
disease and circulating Reactive Protein and IL-6 has been described in a number 
of studies. 
 
CRP (Circulating Reactive Protein) 
C - reactive protein (CRP) is regarded as a biomarker for systemic inflammation, 
and is produced from hepatocytes.  It is a non-specific marker of the acute phase 
response of innate immunity, that can be induced by many stimuli like chronic 
inflammation, trauma and smoking (Blake and Ridker, 2001; Blake et al., 2003). 
In periodontal disease, its secretion is stimulated by circulating cytokines, such as 
TNF-α and IL-1 (Wong, 2008). It is considered a key marker for atherosclerosis 
and high levels of CRP are associated with cardiovascular disease (Blake and 
Ridker, 2003).  
Although many studies have shown that there is an association between 
periodontal disease and the risk of myocardial infarction (Leivadaros et al., 2005; 
Söder et al., 2005), this has not been shown to necessarily be a causal 
association. Several cross-sectional (case-control) studies have shown that CRP 
levels were higher in both aggressive (Havemose-Poulsen et al., 2006; Salzberg 
et al., 2006) and chronic periodontitis subjects than healthy controls (Fredriksson 
et al., 1999; Liu et al., 2010; Loos et al., 2000; Pradeep et al., 2010).  
On the other hand, other studies have concluded that serum CRP concentrations 
were not associated with periodontal disease as there was no difference in Serum 
CRP levels between groups of chronic periodontitis and healthy controls (Tüter et 
al., 2007; Yamazaki et al., 2005).  
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 Interestingly, many interventional longitudinal (treatment) studies using different 
periodontal treatment modalities have shown that serum CRP levels were reduced 
significantly after using periodontal treatment including the use of systemic or local 
sub- and antimicrobial medications (D'Aiuto et al., 2005b; D’Aiuto et al., 2004; 
Golub et al., 2010; Katagiri et al., 2009; Mattila et al., 2002; Renvert et al., 2009; 
Seinost et al., 2005). However, Offenbacher and co-workers have reported in their 
randomised clinical trial that serum CRP levels were not affected by root surface 
debridement especially when its’ level was less than 3mg/L.  
In a systematic review of the relationship between CRP & periodontal disease it 
was concluded that periodontal inflammation can induce a mild acute phase 
response with an increase of CRP levels, and all the included studies showed that 
CRP levels were elevated in periodontitis subjects compared with healthy 
controls. Furthermore periodontal treatment lowers CRP levels (Paraskevas et al., 
2008).  
In addition, a recent meta-analysis has concluded that periodontal treatment 
reduces CRP levels and improves endothelial function, especially in patients with 
CVD and diabetes (Teeuw et al., 2014).  
                                                                                                                                                                                                                                                        
IL-6 (Interleukin-6) 
IL-6 is a major mediator of the inflammatory response which is involved in the 
induction of acute phase proteins and the induction of fever.  It is a multifunctional 
pluripotent pro-inflammatory cytokine produced by many activated cell types 
including monocytes, B lymphocytes, endothelial cells and fibroblasts. However, 
it needs a stimulus to be produced and cannot be just released from intact normal 
cells. It is an important molecule in the regulation of immune response and host 
defence reaction and in the transition between acute and chronic inflammation, it 
is involved in many homeostasis processes including induction of immunoglobulin 
production, T-cell differentiation, stem cell proliferation etc. it is highly expressed 
in many autoimmune diseases like Rheumatoid Arthritis (RA) & psoriasis (Hirano 
et al., 1988), as well as in acute and chronic inflammatory disease such as sepsis 
and atherosclerosis (Beckman et al., 2005; Schlüter et al., 2002). 
IL-6 has a potential role in driving the destructive process of periodontal disease, 
by acting as a pro-inflammatory cytokines alongside IL-1 & TNF-α. It is a bone  
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 resorbing factor, and it causes a dose-dependent inhibition of bone formation in 
vitro (Hughes and Howells, 1993). Surprisingly, some studies show that IL-6 
promotes soft tissue formation. In addition, IL-6 release can balance the pro-
inflammatory effect of IL-1 & TNF-α, by inhibiting their production. So IL-6 may 
have both important destructive and protective effects (Irwin and Myrillas, 1998). 
Most studies have shown that the levels of IL-6 are raised both locally in 
periodontally inflamed sites (Guillot et al., 1995; McGee et al., 1998) and 
systemically in peripheral blood of patients with periodontal disease (Buhlin et al., 
2003; Loos et al., 2000). These elevated levels of IL-6 can stimulate hepatocytes 
to produce CRP and other Acute Phase Proteins to protect the host (Irwin and 
Myrillas, 1998; Loos, 2005). Moreover, Raunio and co-workers’ cross-sectional 
study of 52 subjects with chronic periodontitis concluded that serum IL-6 levels 
increase with periodontal severity (Raunio et al., 2007). In contrast, a cross-
sectional study on Japanese elders’ cohort of 74 healthy and 84 chronic 
periodontitis showed there were no significant relationship between serum IL-6 
levels and the severity of periodontitis (Furugen et al., 2008). 
Interestingly, some studies showed that serum IL-6 levels increase immediately 
after subgingival instrumentation (D’Aiuto et al., 2004; Ide et al., 2004), but drop 
significantly after periodontal treatment and resolution of inflammation (D’Aiuto et 
al., 2004). 
 
Therefore, there are number of issues emerging regarding links between local and 
systemic inflammation to consider in the context of diagnostic biomarkers of 
periodontal disease: 
1. Does local inflammation correlate with systemic inflammation? 
2. Are systemic inflammatory markers potentially useful biomarkers of 
periodontal disease? 
3. Are local biomarkers useful in assessing systemic inflammation? 






1.2 Summary and Aims of the Project 
 
In summary there is considerable interest in the identification, validation and 
clinical application of salivary biomarkers in periodontal disease. Due to the fact 
that periodontal disease is a world-wide health issue and a major cause of tooth 
loss. Therefore, we all as periodontists are aiming to improve early diagnosis and 
management of periodontal disease. 
The literature is rich with studies looking for biomarkers with promising periodontal 
diagnostic utility, and MMP-8 is the most studied one. In addition, results from 
previous studies in our laboratory have identified three AMPs HNP1-3, S100A8 
and LL-37, using mass spectrometry techniques, as potential diagnostic 
biomarkers for periodontal disease (Mulli, 2012).    
Consequently there is scope to extend these previous studies in the study of 
potential periodontal biomarkers.  Firstly there is the opportunity to extend and 
validate our previous observations of the use of AMPs as diagnostic biomarkers, 
by using a standardised salivary collection method for a reference population to 
determine cut off points for salivary AMP concentrations, then applying them to 
an independent cohort with saliva samples collected using the same method in 
order to validate the AMP cut-off points.  Furthermore combinations of biomarkers 
can be tested for improved performance compared with single biomarkers alone.  
Secondly there is the opportunity to carry out a longitudinal study of participants 
undergoing treatment. This would allow us to investigate the effects of treatment 
on the concentrations of these biomarkers.  Most importantly it will also allow us 
to test if these biomarkers have any prognostic significance, such that their 
salivary concentrations may be associated with good or poor responses to initial 
therapy.  Thirdly collection of samples during a longitudinal study will also allow 
the possibility of using samples to investigate the discovery of novel prognostic 




Therefore the aims of the studies in this project are: 
I. Investigate the use of a combination of the antimicrobial peptides 
HNP1-3, LL-37 and S100A8 and the proteolytic enzyme (MMP-8) as 
diagnostic biomarkers of periodontal disease. 
II. Investigate the use of salivary AMPs as prognostic biomarkers in 
longitudinal studies of nonsurgical periodontal treatment; 









CHAPTER 2- VERIFICATION & VALIDATION OF 
SALIVARY BIOMARKERS AS DIAGNOSTIC 





2. Verification and validation of salivary biomarkers as 




In a previous study in our lab Dr.T Mulli identified three AMPs (HNP1-3, S100A8 
and LL-37) as potential diagnostic biomarkers, using mass-spectrometry 
techniques. Unfortunately, he was unable to validate his results in an independent 
cohort of subjects, due to the different saliva collection methods that were used. 
In the original cohort of Dr. Mulli a salivette technique was used to collect the 
saliva, while in the independent cohort a spitting method was used. He 
investigated the difference between the two methods and discovered that the 
salivary AMPs concentrations collected by salivette technique were 10 times less 
than the ones collected by spitting methods (Mulli, 2012).   
Therefore, in order to validate these recently identified AMPs as potential 
biomarkers for periodontal disease, first we have to determine a cut-off point for 
every biomarker. This also would allow us to confirm these original findings in a 
new cohort of samples collected by the spitting method selected on the basis of 
their periodontal diagnosis.  Then we could compare the results of AMPs with 
salivary MMP-8 concentrations, which appear to be the best published marker for 
periodontal disease to date. In addition, we can investigate the value of combining 
biomarkers. Once all these steps were done we can validate our result in an 
independent cohort.      
To validate means to test the external validity of results obtained in one 
experiment. Specifically, this means to test if the results obtained are also 
applicable in independent samples. Therefore, validation studies are crucial as it 
is the only way to have a novel, feasible and accurate technology in order to attain 
definitive point-of-care assessment of individuals` periodontal health status (Li et 
al., 2005). 
In general, there is a need for better biomarkers in order to enhance 
diagnosis/prognosis and monitor the treatment response in many diseases. 
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Although proteomic techniques give a hope for discovery of novel biomarkers, the 
results are not satisfactory so far. This is mainly due to the lack of proper validation 
methods (Rifai et al., 2006). 
The validation process is the last, though not the least, step in the development 
of novel protein biomarker candidates (Rifai et al., 2006) Figure 2-1. The steps 
briefly are: 
1. Discovery: which means the identification of candidate biomarkers that is 
differentially expressed between health and disease. 
2. Qualification: This confirms the differential abundance of the discovered 
candidate in human sample. 
3. Verification: in which the sensitivity of biomarker candidate is confirmed, 
and specificity commences to be tested. 
4. Validation and clinical assay development: where sensitivity and 




Figure 2-1: Flow chart illustrating the steps for the development of novel protein 
biomarker candidate (Acknowledgment: (Rifai et al., 2006)).   
 
The validation process aims to investigate the validity of the identified biomarkers 
against a heterogeneous mass of patients, to ensure its’ diagnostic utility. 
Consequently, establishing a test threshold for disease detection by providing test 
sensitivity and specificity. Therefore, in this study we used Receiver Operating 
Characteristic (ROC) curve in order to determine the best cut-off point for a given 
biomarker values .i.e. where to draw the line between health and disease for 
example.  
The ROC curve is an informative and fundamental tool for diagnostic test 
evaluation. In a ROC curve the true positive rate or values (TPR or sensitivity) is 
plotted on the (y-axis) against false positive rate or values (FPR or 1- specificity) 
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on the (x-axis) for different cut-off points of a parameter Figure 2-2. Each point on 
the ROC curve represents a sensitivity/specificity pair corresponding to a 
particular decision threshold. Maximising sensitivity corresponds to some large (y) 
value on the ROC curve, while maximising specificity corresponds to a small (x) 
value on the ROC curve. That is why the best cut-off point choice is the value that 
correspond to a point nearest to the upper left corner on the ROC curve graph, as 
shown on Figure 2-2; the perfect classification point (0,1). The area under the 
ROC curve (AUC) is a measure of how good a parameter can differentiate 
between two diagnostic groups (healthy/diseased) (Zweig and Campbell, 1993). 
 
 
Figure 2-2: ROC curve graph showing the dimensions that determine the 
classification of a test as either perfect, better or hopeless.  (Acknowledgement: 
(Online Wikipedia, ROC curve)). 
*FPR= False Positive Rate, *TPR= True Positive Rate  
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There is a wealth of research in the literature suggesting MMP-8 as a potential 
biomarker for periodontal disease for health and disease (Adina Bianca Boşca, 
2012; Sorsa et al., 2011; Sorsa et al., 2004). Therefore it is also of considerable 
relevance to compare our own putative biomarkers with MMP-8. 
In addition, it has been suggested that it may be useful or necessary to combine 

























2.2 Aims & Objectives 
 
Therefore the aims of this cross sectional study were: 
1. To identify suitable cut-off points for diagnostic testing for periodontal 
disease of the salivary AMPs: HNP1-3, S100A8 & LL-37.  
2. To compare the diagnostic utility of salivary MMP-8 with the salivary AMPs 
tested.  
3. To investigate the periodontal diagnostic utility of combined salivary 
biomarkers (MMP-8 + HNP1-3 + S100A8, MMP-8+HNP1-3, MMP-
8+S100A8, and HNP1-3+S100A8) compared to individual markers. 
4. To validate these biomarkers as putative diagnostic markers for 





2.3 Materials and Methods for the Original Cohort  
 
2.3.1 Ethical Approval 
The protocol for this study was reviewed and approved by the Outer North East 
London Research Ethics Committee on 27th May 2010, reference number: 
(10/H0701/72). All the participants signed an informed written consent form. 
 
2.3.2 Inclusion Criteria 
The target patients (males and females of any ethnicity), who had been included 
in this study, were between the ages 18 to 65 years and had periodontal disease 
(G, ChP or AgP). Smokers and diabetics were included. 
Case Definitions 
Moderate and severe Chronic Periodontitis were defined as below from the CDC 
/AAP criteria (Page and Eke, 2007) as described in Chapter 1(1.1.2): 
a) Moderate Periodontitis: 
a. Patients with two or more interproximal sites with clinical 
attachment loss of ≥ 4mm occurring at two or more different teeth 
OR two or more interproximal sites with a probing depth of ≥ 5mm, 
not on the same tooth. 
b) Severe Periodontitis: 
a. Patients with two or more interproximal sites with clinical 
attachment loss of ≥ 6mm not on the same tooth, and the presence 
of one or more interproximal sites with a probing depth of ≥ 5mm. 
Aggressive periodontitis cases were defined according to (Demmer and 
Papapanou, 2010) suggestion which they base on that this severity of destruction 
would not be commensurate with the amount of plaque present irrespective of 
plaque control: 
a) In patients ≤25 years of age, the presence of two or more interproximal, 
nonadjacent sites with attachment loss of ≥4 mm occurring at a minimum 
of two different teeth and accompanied by bleeding on probing, will signify 
aggressive periodontitis.  
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b) In individuals between 26 and 35 years of age, a diagnosis of aggressive 
periodontitis will require the presence of two or more interproximal, 
nonadjacent sites with attachment loss of ≥6 mm occurring at a minimum 
of two different teeth and accompanied by bleeding on probing. 
In terms of disease distribution, both localised (≤30% of sites involved) and 
generalised (>30% of sites involved) types were included as long as they are 
following the above mentioned case definitions. 
While for the control group (gingivitis /mild periodontitis case) patients with less 
than two sites with clinical attachment loss of ≥ 4mm and bleeding on probing. 
2.3.3 Exclusion Criteria 
Patients were excluded if they had previous periodontal treatment (including 
antimicrobials) in the last 6 months, were taking any relevant medication or had 
any systemic disease known to affect the periodontal tissues.  
2.3.4 Sample Acquisition  
Based on our previous pilot data we calculated that a sample size of 35 in each 
group would give 80% power at P < 0.05, to detect a 60% mean change in HNP 
concentration between control and diseased samples assuming a mean of 3µg/ml 
in control samples and standard deviation of 3.  
A total of 133 unstimulated saliva samples were used in this study out of which 84 
samples were collected as disease groups, 46 with chronic periodontitis and 38 
with aggressive periodontitis from new patients attending the periodontal 
consultant`s clinic at Guy`s Dental Hospital. A total of 49 unstimulated saliva 
samples with gingivitis/mild periodontitis were used as the control group ; 19 
samples were collected from new patients attending the periodontal consultant’s 
clinics at Guy’s Dental Hospital and 30 samples from non-diabetic patients with 
gingivitis (control group) were obtained from the cohort of samples given to us by 
Dr.Penny Hodge and colleagues from University of Glasgow (Hodge et al., 2012) 
(refer to the next section for more details regarding material and methodology of 
this group). Unfortunately, AMP data were not available for all of the control group 
samples as some samples were too depleted to complete all analyses.  
The whole saliva was collected using the spitting method (by asking the participant 
to spit in a laboratory universal tube for 5 min). Samples were processed 
(centrifuged at 3000 rpm for 15min at 4 ͦ C and aliquots of approximately 300µl) 
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then stored immediately in minus 80ᵒC freezer until time for analysis. Some of the 
samples were collected by Dr. W-C Cheng and Miss J Tebbutt (third year 
undergraduate dental student at King’s). The saliva sample acquisition method 
was the same for all groups. 
2.3.5 ELISAs 
ELISAs for MMP-8, HNP1-3, LL-37 and S100A8 were carried out on all saliva 
samples. To quantify MMP-8, the human total MMP-8 DuoSet kit (R & D Systems, 
inc. USA) was used according to the manufacturer’s instructions. HNP1-3 and LL-
37 proteins commercial kits for HNP1-3 and LL-37 (Hycult biotechnology b.v The 
Netherlands) were used, while Circulex S100A8 (Human) ELISA kit (CYclex Co., 
Ltd.Terasawaoka, Japan) commercial kit was used to quantify S100A8 protein 
according to manufacturer’s instructions (See Appendix 5.1.1 for detailed 
protocols). 
In brief, saliva samples and ELISA reagents were thawed at room temperature. 
The samples for saliva were diluted at an optimized dilution factor of (X 300) for 
MMP-8 (Serial Dilution D1= 1:10, D2=1:30), (X 5000) for HNP1-3 (Serial Dilution 
D1=1:250, D2=1:20), (x 5) for LL-37 and (x 100) for S100A8 (with second reading 
of the plates at 405nm for high concentration samples). Both standards and 
samples were run in duplicates. Colorimetric reading was done using Dynex 
Revelation® 4.24 at 450nm. Standard curves were plotted using Microsoft 
Windows® Excel 2010 spreadsheet software. 
2.3.6 Data Analysis 
Statistical analysis was carried out using Prism® 6 (v 6.04) for Windows MS 
(GraphPad Software Inc., California, USA). One-way analysis of variance 
(ANOVA) was used to analyse the difference in expression of more than two 
analytes in different periodontal disease. While in case where only two analytes 
were tested, two-tailed unpaired t-test was performed. Statistical significance was 
set at p ≤ 0.05.  
Receiver Operating Characteristic Curves (ROC curve) were constructed for 
those analytes that showed a significant difference in expression, and cut-off 
points determined for optimum utility to discriminate between gingivitis and 
periodontitis.  In general cut-off points were chosen particularly to maximise 
specificity, even at the expense of some sensitivity. In addition, biomarkers were 
combined to give a single cut off point, using two different methods: 
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1. Normalised Data Method (NDM):  
In order to combine the biomarkers objectively each value for all biomarkers was 
normalised by dividing the actual concentration by the optimal (predetermined) cut 
off value such that an original biomarker cut-off point concentration was 
normalised to a score of 1 Figure 2-3.  The new normalized values for every 
sample were added together to form a new combined value. These new set of 
data were used to construct a new ROC curve, which produced a combined 
sensitivity and specificity at any combined cut-off point. 
 
Figure 2-3: Diagram showing the principles of the Normalised Data Method for 
combining biomarkers.  After normalising data for each biomarker so that the cut-
off point of each biomarker = 1, the results for each biomarker are added to give a 
combined cut off point, in this case the value 1.  In the example here the actual 
values of 2 biomarkers are combined (HNP1-3 (x) +S100A8 (y) = combined value); 
where 3 biomarkers are to be combined, they are all added together (x+y+z = 


















































2. Any Positive Value Test (APVT): 
This involves assigning each analyte sample result as positive or negative based 
on the pre-chosen cut-offs; so if the AMPs concentration of the sample was equal 
or below the cut-off point then the sample would be assigned as negative 
otherwise it would be positive. Then in order to combine both AMPs we consider 
the combined marker for each sample to be positive if any of the tested biomarkers 
were positive. The combined marker will be negative only when all biomarkers are 
negative. By Using GraphPad Prism 6 software to analyse the contingency table 
using Fisher`s exact test, the sensitivity and specificity of the combined biomarker 
can be achieved. 
 
These cut-off points of the combined data were subsequently applied to salivary 
biomarkers’ levels in an independent cohort originally collected to investigate 
effects of diabetes on periodontitis.  
 
2.4 Material & Methods for the Independent Cohort  
For the control and independent groups, the saliva samples were generously 
given by Dr. Penny Hodge and colleagues of University of Glasgow.  These 
samples were collected as part of a study of the effect of type I diabetes on risk of 
periodontitis, so consequently were chosen for their diabetic status (no diabetes, 
Type I DM with good glycaemic control, Type I DM with poor glycaemic control) 
and then only subsequently received a periodontal assessment. 
  
2.4.1 Ethical Approval 
The  protocol  for  that  study  was  approved  by  the  local  research  ethics 
committee,(Glasgow Royal Infirmary Research Ethics Committee, NHS Greater 




2.4.2 Inclusion Criteria  
As mentioned earlier, the recruitment for this group was based on patients` 
diabetic and not periodontal status. Subjects who had been diagnosed with type I 
diabetes for a minimum of 5 years, were aged between 20 and 55 years and had 
been non-smokers for a minimum of 5 years before being enrolled in the study. 
blood samples were taken from the control participants to confirm they were 
definitely controls and not in pre-diabetic state (Glycosylated haemoglobin 
(HbA1c) < 5.9%). All participants had to have not less than 20 natural teeth 
(Hodge et al., 2012).   
Cases were classified as healthy, gingivitis/mild periodontitis (control group), 
moderate periodontitis or severe periodontitis (disease group) based on the 
number of sites with predetermined threshold of clinical attachment loss (CAL) 
Table 2-1. 
Diagnosis Criteria 
Gingivitis/ Mild periodontitis < 2 sites with CAL* ≥ 4mm & BoP** 
Moderate periodontitis ≥ 2 sites with CAL ≥ 4mm but < 6mm 
Severe periodontitis ≥ 2 sites with CAL ≥ 6mm 
*CAL = Clinical Attachment Loss, **BoP = Bleeding on Probing  
Table 2-1: summary of the case definition criteria.  
 
2.4.3 Exclusion Criteria 
Any participant with any of the following criteria was excluded from the study: 
pregnant, immunosuppressant, on medications with side effect on oral cavity, on 
antibiotics or anti-inflammatory drugs within the previous 6 weeks and who had 
less than 20 teeth and smoking for the last 5 years.  
 
2.4.4 Sample Acquisition  
A total of 193 saliva samples with well or poorly controlled diabetes and non-
diabetics, of this independent cohort, were used in this study, which overall 
included 131 subjects with gingivitis/mild periodontitis, 48 subjects with moderate 
periodontitis and only 14 subjects with severe periodontitis. The saliva sample 




The ELISA tests for the salivary biomarkers of the independent cohort were 
carried out by Dr. T.Mulli and some by Dr. N.Imam (under my supervision) and Dr. 
O.Patel, using the same commercial kits and following the manufacturer’s 












There were a total of 103 saliva samples available for HNP1-3 analysis using 
ELISA; 48 with gingivitis, 41 with chronic periodontitis and 14 with aggressive 
periodontitis. 
The mean concentration of HNP1-3 in gingivitis was 1.65 µg/ml (SD 3.40 µg/ml); 
chronic periodontitis was 9.05 µg/ml (SD 9.30 µg/ml); and aggressive periodontitis 
10.17 µg/ml (SD 9.05 µg/ml). 
The three diagnostic variables were statistically analysed using one-way Analysis 
Of Variance (ANOVA) test which revealed significant differences in the HNP1-3 
levels of chronic periodontitis and aggressive periodontitis compared to gingivitis 
(P<0.0001).  There was no significant difference in HNP1-3 levels between 





Figure 2-4: Vertical scatter graph of salivary HNP1-3 concentrations measured 
using ELISA, showing greater levels in both chronic periodontitis (CP) and 
aggressive periodontitis (AgP) than in gingivitis (G) by ANOVA. 
 
ROC curves were constructed for the data (Gingivitis vs Chronic Periodontitis, and 
Gingivitis vs Aggressive Periodontitis) and showed that HNP1-3 can differentiate 
between gingivitis and chronic periodontitis with specificity of 91.84% and 
sensitivity of 73.81%  at a cut-off salivary HNP1-3 concentration of > 3.675 µg/ml 
(p<0.0001) Figure 2-5. In addition, HNP1-3 was able to discriminate between 
gingivitis and aggressive periodontitis at cut-off salivary HNP1-3 concentration of 
> 2.815 µg/ml, with 83.67% specificity and 93.33% sensitivity (p<0.0001) Figure 
2-6.   
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Figure 2-5: ROC curve construct for salivary HNP1-3 that distinguish between 
gingivitis and chronic periodontitis. 
 
 
Figure 2-6: ROC curve construct for salivary HNP1-3 to distinguish between 
gingivitis and aggressive periodontitis.  
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There were a total of 113 saliva samples available for LL-37 ELISA analysis; 37 
cases with gingivitis, 39 with chronic periodontitis and 37 with aggressive 
periodontitis. 
The mean concentration of LL-37 for gingivitis was 48.83 ng/ml (SD 54.75 ng/ml), 
chronic periodontitis was 40.21 ng/ml (SD 60.22 ng/ml) and aggressive 
periodontitis was 32.74 ng/ml (SD 27.22 ng/ml). The three diagnostic variables 
were statistically analysed using one way Analysis Of Variance (ANOVA) test 
which revealed no significant difference in the LL-37 levels of the three groups 
(p=0.1).i.e chronic periodontitis and aggressive periodontitis compared to 
gingivitis (p=0.5 & p=0.1 respectively), or between chronic and aggressive 
periodontitis (p=0.5) Figure 2-7. 
 
Figure 2-7: Vertical Scatter graph of salivary LL-37 showing no statistical 
significant differential expression in Gingivitis (G) vs. Chroinc Periodontitis (CP), 
(G) vs. Aggressive periodontitis (AgP) and (CP) vs. (AgP) by ANOVA.  





















There were a total of 52 saliva samples available for analysis by S100A8 ELISA; 
27 cases with gingivitis and 25 cases with chronic periodontitis. Increased 
concentrations of salivary S100A8 were seen with increased severity of 
periodontal disease. There was a significant difference between gingivitis/mild 
periodontitis (88.05 ng/ml ± 181.50 ng/ml; Mean ± SD) and chronic periodontitis ( 
696.60 ng/ml ± 54.61402.32 ng/ml; Mean ± SD) (unpaired t-test; two-tailed p value 
(p<0.0001))  
Figure 2-8.  
 
 
Figure 2-8: Vertical Scatter graph showing statistically significant differential 
expression of salivary S100A8 in Gingivitis vs. Chronic Periodontitis, by unpaired 
t-test (P value is two-tailed).  
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ROC curves were constructed and showed that S100A8 was able to differentiate 
between gingivitis and chronic periodontitis cases with 89.29 % specificity  and 
76.92 % sensitivity at a cut-off salivary S100A8 concentration of > 201.3 ng/ml 
(AUC=0.9, p<0.0001) Figure 2-9. 
 
       
 
Figure 2-9: ROC curve construct for salivary S100A8 with significant ability to 
distinguish between gingivitis and chronic periodontitis. 
 
MMP-8 
There were a total of 128 saliva samples available for MMP-8 analysis using 
ELISA; 47 with gingivitis, 45 with chronic periodontitis and 36 with aggressive 
periodontitis. 
The mean concentration of MMP-8 in gingivitis was 37.73 ng/ml (SD 75.79 ng/ml); 
chronic periodontitis was 358.69 ng/ml (SD 344.27 ng/ml); and aggressive 
periodontitis 342.49 ng/ml (SD 380.95 ng/ml).  















A U C  =  0 .9
 p < 0 .0 0 0 1
76 
 
The three diagnostic variables were statistically analysed using one-way Analysis 
Of Variance (ANOVA) with Bonferroni’s  post-test which revealed significant 
differences in the MMP-8 levels of the three groups (p<0.0001).i.e. chronic 
periodontitis and aggressive periodontitis compared to gingivitis (P<0.0001). 
However, there was no significant difference in MMP-8 levels between chronic 




Figure 2-10: Vertical scatter graph of salivary MMP-8 concentrations measured 
using ELISA, showing greater levels in both chronic periodontitis (CP) and 
aggressive periodontitis (AgP) than in gingivitis (G) by ANOVA. 
ROC curves were constructed for the data (Gingivitis vs Chronic Periodontitis, and 
Gingivitis vs Aggressive Periodontitis) and showed that MMP-8 can differentiate 
between gingivitis and chronic periodontitis with specificity of 91.73% and 
sensitivity of 80.43% at a cut-off salivary MMP-8 concentration of > 82.73 ng/ml 
(p<0.0001) Figure 2-11. In addition, MMP-8 was able to discriminate between 
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gingivitis and aggressive periodontitis at cut-off salivary MMP-8 concentration of 
> 79.73 ng/ml, with 91.67% specificity and 75.68% sensitivity (p<0.0001) Figure 
2-12.  
 
Figure 2-11: ROC curve construct for salivary MMP-8 to distinguish between 
gingivitis and chronic periodontitis. 
 
Figure 2-12: ROC curve construct for salivary MMP-8 to distinguish between 
gingivitis and aggressive periodontitis.  
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AUC (%) P value 
HNP1-3 >3.675 µg/ml 91.84 73.81 90 <0.0001* 
S100A8 >201.3 ng/ml 89.29 76.92 90 <0.0001* 
MMP-8 >82.73 ng/ml 91.67 80.43 90 <0.0001* 
*Statistical significance (p<0.05) 
Table 2-2: Summary of the cut-off point concentrations of salivary HNP1-3, 
S100A8 and MMP-8 that significantly differentiate between Gingivitis and Chronic 
Periodontitis. 
 
In addition, a summary of the number of analysed samples for each biomarker, 
which varied between tests because of either an inadequate remaining volume of 
some samples to run ELISAs for all biomarkers, or some missing AMP control 
data, is shown in Table 2-3: 




HNP1-3 48 41 89 
LL-37 37 39 76 
S100A8 27 25 52 
MMP-8 47 45 92 
 
Table 2-3: summary of the number of saliva samples that were available for 
ELISAs analysis for every salivary biomarker. 
 
The (AgP) cases were not considered in further analyses firstly as they did not 
show any significant difference from CPs, and furthermore there were no AgP 
cases in the independent validation cohort.  
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2.5.2  Testing the diagnostic utility of the composite biomarker 
 After investigating the diagnostic utility of the salivary biomarkers MMP-8, HNP1-
3 and S100A8 individually, to the results of combining two or more of these 
biomarkers in order to create a composite biomarker was tested. Each single 
biomarker had a certain cut-off point that had been chosen with its’ related 
sensitivity and specificity. As many recent studies have advised that the use of 
multiple periodontal biomarkers’ combined specificity and sensitivity data might 
result in more predictive ROC curve than the use of single biomarkers (Gursoy et 
al., 2011; Kinney et al., 2011; Ramseier et al., 2009).  
 
(MMP-8+HNP1-3+S100A8) Composite Biomarker 
A total of 50 cases were available; 25 gingivitis and 25 chronic periodontitis cases 
with complete AMPs data for MMP-8, HNP1-3 & S100A8. The cut off points 
identified earlier in this chapter 2.5.1 were applied to this data (> 82.73 ng/ml for 
MMP-8, > 3.675 µg/ml for HNP1-3 and > 201.3 ng/ml for S100A8).  
Using the first method (Normalised Data Method, NDM) for combining biomarkers 
(described previously) each data point was normalized to its’ pre-chosen cut-off 
point then all 3 biomarkers for the same sample were added together. The 
combined sets of data were used to construct a new ROC curve that produced 
statistically significant ability to discriminate gingivitis from chronic periodontitis 
with combined specificity of 96% and sensitivity of 92% at a combined cut-off point 































*Statistical significance (p<0.05) 
Table 2-4: showing the different parameters of the composite marker (MMP-
8+HNP1-3+S100A8) cut-off point concentration that significantly differentiate 
between Gingivitis and Chronic Periodontitis. 
 
Figure 2-13: ROC curve for the combined normalised values for MMP-8, HNP1-3 
and S100A8 using cut-offs 82.73 ng/ml for MMP-8, 3.675 µg/ml for HNP1-3 and       
201.3 ng/ml for S100A8. 
 
Unpaired t-test analysis of the combined new sets of data (normalised) showed 
that the composite biomarker was able to significantly differentiate gingivitis from 
chronic periodontitis (p<0.0001)  
Figure 2-14.  
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Figure 2-14: Vertical Scatter plot of the summed normalized values of MMP-8, HNP1-
3 and S100A8 showing statistically significant higher mean values in chronic 
periodontitis, using unpaired t-test (two-tailed p value)(p<0.0001). 
 
Using the second method (Any Positive Value Test, APVT) of combining 
biomarkers (described before) every sample was assigned as negative (when 
sample concentration ≤ cut-off point) or positive (when sample concentration > 
cut-off point) according to the pre-chosen cut-off points (82.73 ng/ml for MMP-8, 
3.675 µg/ml for HNP1-3 and 201.3 ng/ml for S100A8) and then added together. 
The combined sample was considered positive if at least one of the markers was 
positive and negative only when all the markers were negative  
Table 2-5.   Fisher`s exact test contingency table analysis, gave a high specificity 















































 Negative Positive 
Gingivitis 22 3 
Chronic Periodontitis 1 24 
 
Table 2-5: A contingency table of the combined (MMP-8, HNP1-3 & S100A8) for 
cases with Gingivitis and Chronic Periodontitis (based on predetermined cut-off 
points). 
 
Biomarker Specificity (%) Sensitivity (%) P value 
(MMP-8+HNP1-
3+S100A8) 
88.89 95.65 <0.0001* 
*Statistical significance (p<0.05) 
Table 2-6: showing the specificity and sensitivity of the combined biomarker 
(MMP-8, HNP1-3 & S100A8) using Fisher`s exact test. 
 
By using this combining biomarker method we were able to detect three CP cases 
more than either biomarker individually. In more detail, the combined marker 
detected three CP cases more than MMP-8 or HNP1-3 alone, and four CP cases 
than S100A8 alone.  
 
(HNP1-3 +S100A8) Composite Biomarker 
A total of 50 cases were available; 25 gingivitis and 25 chronic periodontitis cases 
with complete AMPs data for HNP1-3 & S100A8. As shown earlier in this chapter 
2.5.1 that the thresholds were > 3.675 µg/ml for HNP1-3 and > 201.3 ng/ml for 
S100A8.  
Using the first method (NDM) for combining biomarkers (described before), an 
ROC curve was conducted for the new set of normalised summed data.  The 
composite biomarker (HNP1-3+S100A8) was able to significantly differentiate 
between gingivitis and chronic periodontitis with 92% specificity and 84% 
























*Statistical significance (p<0.05) 
Table 2-7: Showing the different parameters of the composite marker (HNP1-
3+S100A8) cut-off point concentration that significantly differentiate between 




Figure 2-15: ROC curve for the combined normalised values for HNP1-3 and 
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Unpaired t-test analysis of the combined (normalised) new sets of data showed 
that the composite biomarker was significantly lower in gingivitis when compared 




Figure 2-16: Vertical Scatter plot of the summed normalized values of HNP1-3 and 
S100A8 showing statistically significant higher mean values in chronic 
periodontitis, using unpaired t-test (two-tailed p value)(p< 0.0001). 
Using the second technique (APVT) of combining biomarkers (described before) 
every sample was assigned as negative or positive according to the pre-chosen 
cut-off points (3.675 µg/ml for HNP1-3 and 201.3 ng/ml for S100A8) and then 
added together. The combined sample was positive if either of the markers was 
positive, and negative only when both markers were negative Table 2-8. Using 
the Fisher`s exact test contingency table analysis by GraphPad prism software, 
gave a high specificity of 88.89% and sensitivity of 95.65% Table 2-9. 
 Negative Positive 
Gingivitis 22 3 
Chronic Periodontitis 1 24 
 
Table 2-8: A contingency table of the combined (HNP1-3 & S100A8) for cases with 
Gingivitis and Chronic Periodontitis (based on predetermined cut-off points).   
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Biomarker Specificity (%) Sensitivity (%) P value 
(HNP1-3+S100A8) 88.89 95.65 <0.0001* 
*Statistical significance (p<0.05) 
Table 2-9: Showing the specificity and sensitivity of the combined biomarker 
(HNP1-3 & S100A8) using Fisher`s exact test. 
 
Using this technique for combining biomarkers we were able to detect three CP 
cases more than either biomarker individually. More specifically the combined 
marker detected three cases with chronic periodontitis more than HNP1-3 alone, 
and four cases more than S100A8 alone. 
 
(MMP-8+HNP1-3) Composite Biomarker 
A total of 81 cases were available; 40 gingivitis and 41 chronic periodontitis cases 
with complete AMPs data for MMP-8 & HNP1-3. . As shown earlier in this chapter 
2.5.1 that the thresholds were > 82.73 ng/ml for MMP-8 and > 3.675 µg/ml for 
HNP1-3.  
Using the first method (NDM) for combining biomarkers (described before) the 
composite biomarker (MMP-8+HNP1-3) was able to significantly differentiate 
between gingivitis and chronic periodontitis with 97.50% specificity and 80.49% 
























*Statistical significance (p<0.05) 
Table 2-10: Showing the different parameters of the composite marker (MMP-
8+HNP1-3) cut-off point concentration that significantly differentiate between 





Figure 2-17: ROC curve for the combined normalised values for MMP-8 and HNP1-
3 using cut-offs 82.73 ng/ml for MMP-8 and 3.675 µg/ml for HNP1-3.  
 
Unpaired t-test analysis for the combined new sets of data (normalised) showed 
that the composite biomarker was significantly lower in gingivitis when compared 
to chronic periodontitis (p< 0.0001)  
Figure 2-18.  
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Figure 2-18: Vertical Scatter plot of the summed normalized values of MMP-8 and 
HNP1-3 showing statistically significant higher mean values in chronic 
periodontitis, using unpaired t-test (two-tailed p value)(p< 0.0001). 
 
Using the second technique (APVT) of combining biomarkers (described before); 
every sample was assigned as negative or positive according to the pre-chosen 
cut-off points (82.73 ng/ml for MMP-8 and 3.675 µg/ml for HNP1-3) and then 
added together Table 2-11.  Using Fisher’s exact test contingency table analysis 
gave both high specificity of 94.87% and sensitivity of 90.48% Table 2-12. 
 
 Negative positive 
Gingivitis 38 2 
Chronic Periodontitis 4 37 
 
Table 2-11: A contingency table of the combined (MMP-8 & HNP1-3) for cases with 
Gingivitis and Chronic Periodontitis (based on predetermined cut-off points).  



































Biomarker Specificity (%) Sensitivity (%) P value 
(MMP-8+HNP1-3) 94.87 90.48 <0.0001* 
*Statistical significance (p<0.05) 
Table 2-12: Showing the specificity and sensitivity of the combined biomarker 
(MMP-8 & HNP1-3) using Fisher`s exact test. 
 
Using this technique for combining biomarkers was not superior to using individual 
biomarker in detecting CP cases, as both biomarkers MMP-8 and HNP1-3 were 
able to detect the same number of cases (37 CP cases) individually and as this 
composite marker. 
 
(MMP-8+S100A8) Composite Biomarker 
A total of 50 cases were available, 25 gingivitis and 25 chronic periodontitis cases 
with complete AMPs data for MMP-8 & S100A8. As shown earlier in this chapter 
2.5.1 the thresholds were > 82.73 ng/ml for MMP-8 and > 201.3 ng/ml for S100A8.  
Using the first method (NDM) for combining biomarkers (prescribed before); by 
constructed ROC curve for the new set of normalised summed data, the 
composite biomarkers (MMP-8+S100A8) was able to significantly differentiate 
between gingivitis and chronic periodontitis with 100 % combined specificity and 
92 % combined sensitivity at a combined threshold of >1.924 with AUC 98 % 























*Statistical significance (p<0.05) 
Table 2-13: Showing the different parameters of the composite marker (MMP-
8+S100A8) cut-off point concentration that significantly differentiate between 





Figure 2-19: ROC curve for the combined normalised values for MMP-8 and 
S100A8 using cut-offs 82.73 ng/ml for MMP-8 and 201.3 ng/ml for S100A8.  
 
Unpaired t-test analysis for the combined new sets of data (normalised) showed 
that the composite biomarker was able to significantly differentiate gingivitis from 
chronic periodontitis (p< 0.0001) Figure 2-20.  
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Figure 2-20: Vertical Scatter plot of the summed normalized values of MMP-8 and 
S100A8 showing statistically significant higher mean values in chronic 
periodontitis, using unpaired t-test (two-tailed p value)(p< 0.0001). 
 
Using the second technique (APVT) of combining biomarkers (described before) 
every sample was assigned as negative or positive according to the pre-chosen 
cut-off points (82.73 ng/ml for MMP-8 and 201.1 ng/ml for S100A8) and then 
added together. The combined sample was scored positive if either of the markers 
was positive and negative only when both markers were negative Table 2-14. 
Using the Fisher`s exact test contingency table analysis by GraphPad prism 
software, gave both high specificity of 92.31% and sensitivity of 95.83% Table 
2-15. 
 
 Negative Positive 
Gingivitis 23 2 
Chronic Periodontitis 1 24 
 
Table 2-14: A contingency table of the combined (MMP-8 & S100A8) for cases with 
Gingivitis and Chronic Periodontitis (based on predetermined cut-off points).  
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Biomarker Specificity (%) Sensitivity (%) P value 
(MMP-8+S100A8) 92.31 95.83 <0.0001* 
*Statistical significance (p<0.05) 
Table 2-15: Showing the specificity and sensitivity of the combined biomarker 
(MMP-8 & S100A8) using Fisher`s exact test. 
 
Using this technique for combining biomarkers we were able to detect three cases 
with Chronic Periodontitis more than either biomarker individually. More 
specifically the combined marker detected four cases with chronic periodontitis 
more than S100A8 alone, and three cases more than MMP-8 alone. 
Overall comparison of the results of the two methods of combining biomarkers 
reveals that the first method (NDM) was slightly more specific but less sensitive in 
detecting disease/healthy cases than the second (APVT). A summary table of the 
biomarkers combination results using the two different methods of combination 





















50 96 92 88.89 95.65 
(HNP1-
3+S100A8) 
50 92 84 88.89 95.65 
(MMP-
8+HNP1-3) 
81 97.50 80.49 94.87 90.48 
(MMP-
8+S100A8) 
50 100 92 92.31 95.83 
 
Table 2-16: Summary of the composite biomarkers comparing the results of the 
two combining methods.  
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2.5.3 The application of pre-determined cut-off points for MMP-8, 
HNP1-3 & S100A8 to an independent cohort to diagnose 
periodontal disease 
The results above suggest that salivary MMP-8, HNP1-3 and S100A8 individually 
and as a composite biomarker have the ability to differentiate between gingivitis 
and chronic periodontitis with fairly high specificity and sensitivity. In order to 
validate this observation, and particularly to test the cut-off points for a positive 
test determined in the previous study, we tested the ability of these biomarkers to 
detect periodontal disease in an independent cohort of subjects which had been 
collected on the basis of their diabetic status and thus were of continuously 
variable periodontal disease status.  




















59 29 7 95 
Total number 
 
131 48 14 193 
 
Table 2-17: Showing the distribution of the independent cohort subjects 
according to the diabetic status and periodontal diagnosis according to the case 
definition. 
 
Within this cohort, the application of the predetermined cut-off points for HNP1-3 
(> 3.675 µg/ml) detected periodontitis with 87.50% specificity and 33.77% 
sensitivity and for S100A8 (> 201.3 ng/ml) 77.63% specificity, 26.09 % sensitivity 
Figure 2-21, Figure 2-22. While for MMP-8 the application of pre-chosen threshold 
(>82.73 ng/ml) detected periodontitis with 80.15% specificity and 37.10% 





Figure 2-21: Vertical scatter plot graph showing the application of HNP1-3 pre-
chosen cut-off (>3.675µg/ml) to the independent cohort.  
 
Figure 2-22: Vertical scatter plot graph showing the application of S100A8 pre-
chosen cut-off (>201.3ng/ml) to the independent cohort.  
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Figure 2-23: Vertical scatter plot graph showing the application of MMP-8 pre-
chosen cut-off (>82.73ng/ml) to the independent cohort. 
Using the first technique (NDM) described before to combine all three biomarkers 
(by normalising the data to the chosen cut-off); a combined cut off point for (MMP-
8 + HNP1-3 + S100A8) (> 2.512) showed 74.55 % specificity, with 25.81 % 
sensitivity Figure 2-24.  
 
Figure 2-24: Vertical scatter plot graph showing the application of the composite 
(MMP-8+HNP1-3+S100A8) pre-chosen cut-off (>2.512) to the independent cohort.   
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Using the second way of combining biomarkers (APVT – any positive value test) 
Table 2-18 gave 42.42 % specificity and 67.92 % sensitivity Table 2-19, which is 
in contrast to the results obtained using the first way of combining biomarkers. 
 
 Negative Positive 
Gingivitis 36 19 
Chronic Periodontitis 17 14 
 
Table 2-18: A contingency table of the combined (MMP-8 + HNP1-3 + S100A8) for 




Biomarker Specificity (%) Sensitivity (%) P value 
(MMP-8+HNP1-3+S100A8) 42.42 67.92 0.4 
 
Table 2-19: Showing the specificity and sensitivity of the combined biomarker 
(MMP-8 + HNP1-3 + S100A8) of the independent cohort using Fisher`s exact test. 
 
For the composite biomarker (HNP1-3 + S100A8) using the combined analytes by 
NDM method the application of the predetermined cut-off point (1.937) was able 





Figure 2-25: Vertical scatter plot graph showing the application of the composite 
(HNP1-3+S100A8) pre-chosen cut-off (>1.937) to the independent cohort.  
 
While by using APVT technique for combining HNP1-3 + S100A8 Table 2-20 gave 
a combined specificity of 46.15 % and sensitivity of 65.85 % Table 2-21. 
 
 Negative Positive 
Gingivitis 54 21 
Chronic Periodontitis 28 18 
 
Table 2-20: A contingency table of the combined (HNP1-3 + S100A8) for cases 
with Gingivitis and Chronic Periodontitis (based on predetermined cut-off points). 
 
Biomarker Specificity (%) Sensitivity (%) P value 
(HNP1-3+S100A8) 46.15 65.85 0.2 
 
Table 2-21: Showing the specificity and sensitivity of the combined biomarker 
(HNP1-3 + S100A8) using Fisher`s exact test.   
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Moreover, the application of the pre-chosen threshold for the composite marker 
(MMP-8 + HNP1-3) (>2.540), by NDM technique, to the independent cohort 
detected periodontitis with 86.26 % combined specificity and 25.81 % combined 
sensitivity Figure 2-26. 
  
Figure 2-26: Vertical scatter plot graph showing the application of the composite 
(MMP-8+HNP1-3) pre-chosen cut-off (>2.540) to the independent cohort. 
 
When the APVT technique was used Table 2-22, the analysis to the independent 
cohort according to the predetermined cut-off gave 47.37 % specificity and 74.26 
% sensitivity Table 2-23. 
 
 Negative positive 
Gingivitis 101 30 
Chronic Periodontitis 35 27 
 
Table 2-22: A contingency table of the combined (MMP-8 + HNP1-3) for cases with 
Gingivitis and Chronic Periodontitis (based on APVT).  








































Biomarker Specificity (%) Sensitivity (%) P value 
(MMP-8+HNP1-3) 47.37 74.26 0.004* 
*Statistical significance (p<0.05) 
Table 2-23: Showing the specificity and sensitivity of the combined biomarker 
(MMP-8+HNP1-3) of the independent cohort using Fisher`s exact test. 
 
In addition, application of composite markers MMP-8 + S100A8 (>1.924), by NDM 
technique, to the independent cohorts was able to detect periodontitis with 
combined 81.82 % specificity and 29.03 % sensitivity Figure 2-27. 
 
  
Figure 2-27: Vertical scatter plot graph showing the application of the composite 
(MMP-8+S100A8) pre-chosen cut-off (>1.924) to the independent cohort. 
 
However when using the APVT technique Table 2-24, the analysis gave 41.38 % 
specificity and 66.67 % sensitivity Table 2-25.  







































 Negative positive 
Gingivitis 38 17 
Chronic Periodontitis 19 12 
 
Table 2-24: A contingency table of the combined (MMP-8 + S100A8) for cases with 
Gingivitis and Chronic Periodontitis of the independent cohort (By APVT). 
 
Biomarker Specificity (%) Sensitivity (%) P value 
(MMP-8+S100A8) 41.38 66.67 0.5 
 
Table 2-25: Showing the specificity and sensitivity of the combined biomarker 
(MMP-8+S100A8) of the independent cohort using Fisher`s exact test. 
 
A summary of the results for individual and combined biomarkers is shown in 
Table 2-26. 
 
Biomarker Specificity (%) Sensitivity (%) P value 
HNP1-3 87.50 33.77 0.08 
S100A8 77.63 20.09 0.6 
MMP-8 80.15 37.10 0.01* 
(MMP-8+HNP1-3+S100A8) 74.55 25.81 0.7 
(HNP1-3+S100A8) 78.67 23.91 0.5 
(MMP-8+HNP1-3) 86.26 25.81 0.01* 
(MMP-8+S100A8) 81.82 29.03 0.6 
*Statistical significance (p<0.05) 
Table 2-26: Summary of the application of pre-determined cut-offs results, for 




2.5.4 The effects of diabetes mellitus on biomarker status 
Although previous pilot data in our lab had suggested that there were no 
differences in salivary biomarkers due to the diabetic status of the subjects we 
tested this further by 2-way ANOVA using periodontal disease status (healthy, 
gingivitis / mild periodontitis, and moderate to severe periodontitis) and diabetic 
status (no diabetes, well–controlled diabetes and poorly controlled diabetes) as 
explanatory variables.  Bonferroni Post-Tests were used to identify significant 
differences between each data category.   
The results for MMP-8 are shown in Table 2-27 and Figure 2-28.  There was a 
significant effect of diabetes and periodontal status on the concentrations of MMP-
8 and a significant interaction between periodontal disease and diabetes. 
The effect of Diabetes was not significant in the absence of any periodontal 
disease. 
 
Two-way ANOVA for MMP-8  
Source of Variation % of total variation P value 
Interaction 5.36 0.02* 
Diabetes 6.13 0.001* 
Perio 9.69 < 0.0001* 
   
Bonferroni post-tests  
   
No Diab vs Well controlled  
No Perio  > 0.05 
Mild Perio  < 0.01* 
severe  < 0.05* 
   
No Diab vs poorly controlled  
No Perio  > 0.05 
Mild Perio  < 0.01* 
severe  < 0.05* 
*Statistical significance (p<0.05) 
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Figure 2-28: Bar graph illustrates the significant influence of DM on MMP-8 in mild 
and moderate-severe periodontitis. 
 
The results for HNP are shown in Table 2-28 and Figure 2-29.  There was no 
significant effect of diabetes or periodontal status on the concentrations of HNP 
and no significant interaction between periodontal disease and diabetes. 
 
Two-way ANOVA for HNP  
Source of Variation % of total variation P value 
Interaction 0.09 1 
diabetes 0.04 1 
Perio 0.25 0.8 
 
Table 2-28: Summary Results of 2-way ANOVA for HNP.  
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Figure 2-29: Bar graph illustrates the non-significance influence of DM on HNP1-3 
in different periodontal diagnoses. 
The results for S100A8 are shown in Table 2-29 and Figure 2-30.  Overall there 
was a significant effect of periodontal status on the concentrations of S100 and a 
significant interaction between periodontal disease and diabetes, but no direct 
significant of diabetes.  Bonferroni post-tests were all non-significant. 
Two-way ANOVA of S100a8  
Source of 
Variation 
% of total 
variation 
P value 
Interaction 5.61 0.02* 
Diabetes 0.84 0.4 
Periodontal disease 4.28 0.01* 
   
Bonferroni post-tests  
No Diab vs Well controlled  
No Perio  P > 0.05 
Mild Perio  P > 0.05 
severe  P > 0.05 
No Diab vs poorly controlled  
No Perio  P > 0.05 
Mild Perio  P > 0.05 
Severe  P > 0.05 
*Statistical significance (p<0.05) 
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Figure 2-30: Bar graph illustrates the effects of DM on S100A8 in different 






2.6  Discussion 
 
The main objectives of this study were to verify and establish a diagnostic 
threshold for a group of salivary biomarkers (MMP-8, HNP1-3, S100A8 and LL-
37) and to test the validity of the diagnostic utility of these biomarkers. This 
involved the determination of optimal cut off points using samples of known 
periodontal status, and then the application of these previously determined cut-off 
points to an independent cohort of subjects.  
The independent group was a particularly good test for this study as the 
participants were recruited based on their diabetic and not periodontal status. This 
cohort comprised of relatively young individuals (mean age of 36 years) who were 
non-smokers for at least 5 years, and approximately 2/3rds with type I diabetes. 
However, most of them had only mild periodontal disease. 
In the first series of experiments to establish cut off points for salivary AMPs and 
to compare these results with salivary MMP-8, our findings firstly confirmed 
previous results in our lab of the potential diagnostic utility of HNP1-3 and S100A8.  
The ELISA analysis for the salivary antimicrobial peptides showed that HNP1-3 
and S100A8 concentrations could differentiate between gingivitis and chronic 
periodontitis with high specificity (around 90%) and around 75% sensitivity.  This 
is similar to the findings of previous studies for S100A8 which have reported that 
their levels in GCF and saliva are elevated in periodontitis (Kido et al., 1999; 
Kojima et al., 2000; Ramseier et al., 2009). Likewise, α-defensins (HNP1-3) GCF 
levels have been reported to be  higher in chronic and aggressive periodontitis 
than healthy controls (Puklo et al., 2008), although other studies have reported 
that there was no significant difference in the HNP1-3 concentrations between 
diseased and healthy periodontium (Lundy et al., 2005; Turkoglu et al., 2010). 
On the other hand, LL-37 concentrations were not significantly different between 
disease and control groups, which is in contrast with the findings of Turkoglu and 
colleagues (Türkoǧlu et al., 2009) of elevated levels of LL-37 in patients with 
chronic periodontitis as well as our previous studies that showed LL-37 was 
specifically elevated in Aggressive Periodontitis (Mulli, 2012). Subsequently, LL-
37 was thus not investigated further in our subsequent studies. 
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When comparing our results for HNPs and S100 with those for MMP-8, we found 
that MMP-8 also was able to discriminate between gingivitis and periodontitis 
(chronic and aggressive) with both high specificity and sensitivity.  The results with 
MMPs showed a slightly improved sensitivity compared to the AMPs.  This finding 
is in keeping with reports of MMP-8 a reliable marker for periodontal disease as it 
showed significant high levels in chronic periodontitis compared to healthy 
controls (Miller et al., 2006; Todorovic et al., 2006). However, MMP-8 was unable 
to discriminate chronic from aggressive periodontitis in our study that goes well 
with other study`s finding of no marker in saliva or GCF that could distinguish 
between chronic and aggressive periodontitis (Loos and Tjoa, 2005). 
In addition, our preliminary results regarding aggressive periodontitis showed that 
only HNP1-3 and MMP-8 might has the ability to discriminate between gingivitis 
and aggressive periodontitis cases. However, none of them was able to 
differentiate between chronic and aggressive periodontitis case. 
Combining more than one biomarker may significantly improve the diagnostic 
utility when compared with single biomarker tests (Gursoy et al., 2011; Ramseier 
et al., 2009). All biomarkers combinations that we have performed gave 
exceptionally high specificity and high sensitivity; with the best combination being 
MMP-8 + S100A8 where it was able to detect periodontitis cases with 100 % 
specificity and 92 % sensitivity. However, combining HNP1-3 with any of 
biomarkers MMP-8 or S100A8 did not further improve the diagnostic utility of the 
test compared with combining MMP-8 and S100A8 only.  
We used 2 different methods to combine the biomarker data to produce a 
composite biomarker test, the Normalised Data Method (NDM) which allowed 
summation of different markers by normalising their values first and the Any 
Positive Value Test (APVT) where by a positive value for any single biomarker 
was considered as a positive composite biomarker value.  Both methods produced 
rather similar results although the APVT was somewhat less specific.  This is 
perhaps not surprising given the wide variation of biomarker levels between 
individuals even in control samples. 
We then tested these findings on the independent cohort of samples to test the 
external validity of the results.  This was quite a stringent test as in contrast to the 
initial cohort of samples, which had been collected with discrete periodontal 
diagnoses, the second cohort had been collected on the basis of their diabetic 
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status and their periodontal status was continuously variable.  In addition there 
were relatively low levels of periodontitis overall in this cohort.  The application of 
pre-determined thresholds, either individual or combined cut-offs, were able to 
detect periodontitis with specificity of between around 75 – 85 % but with very low 
sensitivity.  Combination tests using the NDM method tended to be superior to the 
individual markers alone.  Interestingly, using the APVT technique for combining 
biomarkers had improved the sensitivity but at the expense of specificity. 
Although a specificity of around 80+% might potentially be of some use clinically 
in some situations, such as positive identification of “cases” in epidemiological 
studies, these results do not suggest overall that these tests, even in 
combinations, would be useful without additional either clinical or biomarker data.   
Given the excellent results obtained with the original cohort studies, some other 
explanations might help to partially explain the results of the validation study.  Most 
importantly we tested the effects of diabetes on the biomarker levels.  In previous 
pilot studies in our lab we had not seen any evidence of differences between 
groups of different diabetic status.  However here we analysed the cohort allowing 
both for periodontal and diabetic status at the same time by 2-way ANOVA.  This 
analysis showed clearly that MMP-8 levels were elevated in diabetics with mild or 
more severe periodontitis.  In addition although the effect of diabetes on S100A8 
was non-significant, there was significant interaction between the effects of 
periodontal disease and diabetes which also suggests that diabetes may affect 
S100A8 in patients with Periodontal Disease.  These results suggest that the 
biomarker tests carried out here may not be valid on subjects with diabetes or of 
unknown diabetic status.  We considered carrying out the analyses on the non-
diabetic subjects only, but the numbers of cases of severe periodontitis in the non-
diabetic patients were considered too small to be very valid or useful. 
Finally the samples used in the validation study were collected in Glasgow by a 
different research group and although the reported collection method used by 
them appears the same as our own method this might have affected the samples 
if there was any variation.  These samples were shipped to London by Courier on 





Overall the results of the studies in this chapter suggest that MMP-8, HNP1-3 and 
S100A8 may be useful to identify cases of periodontitis with good specificity and 
less good sensitivity and may give superior results when combined, particularly 
using the NDM technique.  The validation study suggests that the test may not be 
useful in patients with diabetes.  Additional validation studies would be useful in 










CHAPTER 3- PROGNOSTIC BIOMARKERS OF 






3. Prognostic Biomarkers of Periodontal Disease: A 
Longitudinal Study 
 
The prediction of patients’ response (outcome) to periodontal treatment remains 
problematic. Due to the complicated nature and multifactorial aetiology of 
periodontal diseases, it has been difficult to identify markers with diagnostic and 
prognostic utility. Currently, clinicians rely on certain criteria (particularly clinical 
findings such as probing pocket depth, bleeding on probing, radiographical 
assessment of alveolar bone loss and also on general factors such as age, 
medical history and smoking) that have been used quite subjectively to identify 
susceptible individuals and active sites. Although these criteria are easy to use, 
their prognostic utility is very limited (Giannobile et al., 2009). Therefore, the idea 
of the identification of a novel, reliable, simple and non-invasive 
diagnostic/prognostic tool for periodontal disease is very interesting and attractive 
to clinical researchers.    
Over recent decades, researchers have targeted oral fluids in order to investigate 
possible prognostic markers. Obviously, finding a single biomarker to detect or 
predict periodontal disease is unexpected due to the complexity of periodontal 
disease. In this matter, the literature is not rich with longitudinal studies looking 
into changes of local and systemic biomarkers during periodontal treatment.  
As already discussed, there can be considerable variations in treatment outcomes 
between individuals, and poor responses to treatment tend to cluster in a minority 
of patients.  In the last chapter 2 we investigated the diagnostic utility of certain 
salivary biomarkers, both singly and combined, and showed a significant ability to 
detect periodontal disease. Therefore, we would like to take this further and 
investigate the potential prognostic utility of these biomarkers in a longitudinal 
intervention study of periodontal treatment.   
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3.1  Aims & Objectives 
The specific aims of this longitudinal study intervention were: 
1. To test the prognostic capability of the recently identified AMPs (HNP1-3 
& S100A8) and MMP-8 individually and in combination on initial outcome 
of nonsurgical periodontal treatment. 
2. To investigate the changes in salivary analytes with time in response to 
periodontal treatment. 
3. To investigate the relationship of salivary analytes to systemic 
inflammatory markers (CRP & IL-6) in circulating blood, at baseline and 
following non-surgical periodontal treatment. 
4. To investigate if these systemic inflammatory markers (CRP, IL-6) have 









3.2 Material and Methods 
3.2.1 Ethical Approval 
The protocol for this study was reviewed and approved by Newcastle and North 
Tyneside Research Ethics Committee 2 on 21st March 2012, reference number: 
(12/NE/0122). All the participants signed an informed written consent form.  
 
3.2.2 Inclusion Criteria 
The participants (males and females from any ethnicity) included in this study were 
generally healthy (smokers and diabetics were included), between the ages 18 to 
65 years and had chronic periodontitis (see case definition below 3.2.4). All 
participants were recruited either from patients’ waiting list or actively from 
consultant-led new patient clinics at the Department of Periodontology at Guy`s 
Dental Hospital. All participants had at least 20 natural teeth. 
 
3.2.3  Exclusion Criteria 
Patients were excluded from the study if the patient had: 
1. Complicating medical history. Anybody taking medication likely to affect 
gingival health, including oral contraceptive pills, calcium channel 
blockers, phenytoin, cyclosporine, and any regular use of anti-
inflammatory medication including corticosteroids and NSAIDS. 
2. Medical conditions likely to affect gingival health, such as pregnancy. 
3. Periodontal treatment within the last 6 months or antimicrobial therapy 
within the last 3 months. 
4. Identifiable blood borne transmissible disease, such as hepatitis.  
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3.2.4  Case Definitions 
Moderate and severe Chronic Periodontitis were defined from the CDC /AAP 
criteria (Page and Eke, 2007) as below:  
a. Moderate Periodontitis: 
Patients with two or more interproximal sites with clinical attachment loss of ≥ 
4mm occurring at two or more different teeth OR two or more interproximal sites 
with a probing depth of ≥ 5mm, not on the same tooth. 
b. Severe Periodontitis: 
Patients with two or more interproximal sites with clinical attachment loss of ≥ 
6mm not on the same tooth, and the presence of one  or more interproximal 
sites with a probing depth of ≥ 5mm. 
In addition, a clinical diagnosis of chronic periodontitis was made by a consultant. 
 
3.2.5  Study Populations & Protocol   
The power calculation for this study was based on comparing the salivary 
biomarker (MMP-8) levels before and after periodontal treatment using a paired 
sample t-test.  Assuming an effect size of 0.4 with 80% power, the study will 
require a total sample of 52 to detect the difference at 5% level of significance. 
The power calculation was carried out using G power version 3.1.5. 
The recruited participants were informed and consented in order to be enrolled in 
the study. As an overview of the protocol, every participant was offered four 
appointments at the department of Periodontology at Guy`s Dental Hospital. At 
the first visit they had a thorough periodontal assessment. During second and third 
visits non-surgical periodontal therapy was carried out (with or without local 
anaesthesia using both manual and ultrasonic scalers). At the final visit a thorough 
reassessment was carried out. In addition, they were asked to provide saliva, 
blood and plaque samples before and after the provided therapy. See Table 3-1 
for full description of the protocol.  
In more detail, at the first study visit, a full history was recorded from every 
participant (after they were fully informed and consented), saliva & blood samples 
were taken and then a full clinical assessment was performed. Smoking status of 
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the participants was either current smoker (self-reported) or non-smoker (never or 
ex-smoker). The periodontal assessment (baseline data) included: plaque index 
(PI= the number of sites with detectable supra-gingival plaque x 100/ the total 
number of sites per mouth), bleeding index (BI= the number of sites with gingival 
bleeding on probing x 100/ the total number of sites per mouth), six point probing 
pocket depth (PPD), gingival recession, tooth mobility and furcation involvement. 
The BI, PPD and gingival recession were measured using a William’s graduated 
probe. Therefore, readings > 10mm in probing pocket depth were omitted from 
analysis.  The number of these sites (>10mm PPD) were small; a total of 15 sites 
in eight subjects.  
At the second study visit, three plaque samples were taken from three deep sites 
of > 4mm probing pocket depth, using paper points and placed in Eppendorf tubes 
and stored at -80°C until time for future analysis. Whenever possible sites from 
both anterior and posterior, and upper and lower teeth were sampled, depending 
on distribution of deep sites.  Then half-mouth supra- & sub-gingival scaling using 
both manual and ultrasonic instrumentations was performed under local 
anaesthetic. At the third study visit, non-surgical root surface debridement was 
performed in the remaining quadrants, and full mouth polishing was performed 
and further OHI was given. Eight to ten weeks later (after completion of the 
treatment), participants were seen for saliva, blood and plaque sampling and 
reassessment of all clinical variables assessed at baseline.  
In addition, oral hygiene instruction was given and plaque & bleeding scores were 
performed at every visit of the study.  All teeth were included except third molars. 
Initially in the study, all demographic data and clinical measurements were 
recorded on the Clinical Study Record Form (see Appendix 5.2.3), while later all 
the data were recorded electronically using clinical information system (SALUD 





 Visit (1) Visit (2) Visit (3) Visit (4) 








X   X   









X     X 
*OHI: Oral Hygiene Instructions, PI: Plaque Index, BI: Bleeding Index.  




A total of eight participants were randomly selected in order to re-measure both 
probing pocket depth (PPD) and recession (Rec) of half-mouth (two quadrants), 
at the same visit (either at baseline or reassessment visits). The side selection 
was random; four participants were selected for the right side and four for the left 
side. All the readings were carried out by the same clinical researcher (BK). A total 
of 560 sites were included in the reproducibility study.  
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3.2.6  Sample Acquisition 
3.2.6.1 Whole saliva sample collection and processing 
Unstimulated whole saliva was collected twice from every participant; at the first 
and last study visits, before starting the clinical periodontal examination. Subjects 
were asked to passively drool into a pre-weighed sterile plastic tube for 5 minutes, 
then the collected tubes were transferred directly into an ice box to be carried to 
the lab at Guy`s Hospital where all the samples were processed and stored. The 
processing procedure of the collected saliva started with weighing the tubes again 
(to get the net saliva volume), vortexing them for 20-30 seconds and centrifuging 
the samples at 3000 rpm at (4°C) for 15 minutes. The processed saliva was 
aliquotted into small Eppendorf Tubes® (500µl capacity), labelled and logged-in 
using a sample tracking software (Pro-curo Software Ltd, UK) and Brady System 
hardware, then stored at - 80°C in freezers until the time for analysis.  
 
3.2.6.2 Blood sample collection and processing 
A volume of 5 ml of venous blood from the antecubital fossa was collected at the 
first and last study visits before commencing the periodontal clinical examination. 
Once the blood drained into gold cap Vacutainer® tubes, it was allowed to clot for 
30 minutes then centrifuged at 2900 rpm at 20°C for 10 minutes. The serum was 
aliquotted into small Eppendorf Tubes® (500µl capacity), labelled and logged-in 
using a sample tracking software (Pro-curo Software Ltd, UK) and Brady System 
hardware. The samples were stored at - 80°C in freezers until the time for analysis.    
 
 
3.2.7 Saliva & Serum Analysis using ELISAs 
3.2.7.1 ELISAs for Saliva Samples 
ELISAs for MMP-8, HNP1-3, and S100A8 were carried out on all saliva samples 
collected from every participant before and after non-surgical periodontal 
treatment. To quantify MMP-8, the human total MMP-8 DuoSet kit (R & D 
Systems, inc. USA) was used to determine the concentrations of MMP-8 
according to the manufacturer’s instructions. HNP1-3 proteins commercial kit for 
HNP1-3 (Hycult biotechnology b.v The Netherlands) was used, while Circulex  
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 S100A8 (Human) ELISA kit (CYclex Co., Ltd.Terasawaoka, Japan) commercial 
kit was used to quantify S100A8 protein according to manufacturer’s instructions 
(See Appendix 5.1.1 for detailed protocols). 
The reported minimum detectable concentrations of HNP1-3 and S100A8 were 
156 pg/ml and 43.4 pg/ml respectively, and the coefficient of variance (intra-assay 
precision) ranges were <10% and between 3.6%-4.1% respectively. 
In brief, saliva samples and ELISA reagents were thawed at room temperature. 
The samples for saliva were diluted at an optimized dilution factor of X 300 for 
MMP-8 (Serial Dilution D1= 1:10, D2=1:30), X 5000 for HNP1-3 (Serial Dilution 
D1=1:250, D2=1:20), and x 100 for S100A8 (with second reading of the plates at 
405nm for high concentration samples). For S100A8, some saliva samples 
showed higher optical density readings than the highest standard (S1), therefore 
were repeated with higher dilution factor (X250). Both standards and samples 
were run in duplicates. Colorimetric reading was done using Dynex Revelation® 
4.24 at 450nm. Standard curves were plotted using Microsoft Windows® Excel 
2010 spreadsheet software. 
 
3.2.7.2 ELISAs for Serum Samples 
ELISAs for CRP and IL-6 were carried out on all serum samples collected from 
every participant before and after the non-surgical periodontal treatment. To 
quantify CRP, the high sensitivity CRP kit (Kalon Biological Ltd, UK) was used to 
determine the concentrations of CRP according to the manufacturer’s instructions. 
High sensitivity Human IL-6 commercial kit for IL-6 (Quantikine® HS ELISA, R&D 
Systems, Inc. USA) was used according to the manufacturer’s instructions. (See 
Appendix 5.2.3 for detailed protocols). 
The minimum detectable dose of CRP was 0.20 mg/L and for IL-6 ranged from 
0.016-0.110 pg/ml, and a coefficient of variation (Intra-assay precision) for CRP 
between 5.2% and 15% and for IL-6 between 6.9% and 7.8%. 
In brief, serum samples and ELISA reagents were thawed at room temperature. 
The samples for serum were diluted at an optimized dilution factor of (X 1000) for 
CRP (Serial Dilution D1= 1:50, D2=1:20). While for IL-6, the serum samples were 
run neat (undiluted). Both standards and samples were run in duplicates.   
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Colorimetric reading was done using Dynex Revelation® 4.24 at 450nm. Standard 
curves were plotted using Microsoft Windows® Excel 2010 spreadsheet software. 
 
3.2.8 Data Entry and Statistical Analysis 
All study data (demographic & clinical) that was recorded on clinical study forms 
or stored in the SALUD software system were transferred manually into an Excel 
spreadsheet for analysis. In addition, biomarker data (from the analysis of 
saliva/blood samples in the lab) was exported to the master Excel spreadsheet of 
the study. For both clinical and protein assay parameters there were paired sets 
of data for every participant .i.e. before treatment vs. after treatment.  
The patient means for all clinical measurements, including plaque and bleeding 
scores, probing pocket depth and gingival recession were calculated.   The 
probing pocket depth analyses were carried out on deep sites only. i.e. single sites 
that measured ≥ 5mm at baseline. In order to determine the initial outcome 
measure to treatment response, we measured the percentage of non-responding 
deep sites. The non-responding deep sites were defined as sites that did not 
improve or deteriorated after the non-surgical periodontal treatment. In detail, at 
site-specific level if the change (pre-operative minus post-operative) in PPD, after 
treatment, was zero or negative, then the site was assigned as non-responsive.  
 
Thus the percentage of non-responding deep sites =  
The number of non-responding deep sites X 100/ Total number of deep sites at 
baseline. 
Postoperatively, participants were classified, based on arbitrarily chosen cut-off (≥ 
50%) of the percentage of non-responding deep sites, to either: 
Responders: those who had less than 50% of their deep sites which did not 
respond to the treatment provided. i.e. sites that showed no improvement in the 
change of their PPD ,  
Non-responders: those who had at least 50% of their deep sites which did not 
respond to the treatment provided. 
The dichotomised outcomes “responder” and “non-responder” were used as the 
primary outcome measure for testing of prognostic markers. 
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For statistical analyses, Excel, SPSS and Prism® 6 (v 6.04) for Windows MS 
(GraphPad Software Inc., California, USA) were used. Univariate analyses were 
carried out to determine: 
1. The change in salivary and serum biomarkers in response to treatment, 
using a paired t-test; 
2. The change in salivary and serum biomarkers between responder and non-
responder subjects, using un-paired t-tests; 
3. The association of pre- and post-operative biomarkers to clinical treatment 
outcomes, using linear regression; 
4. The association of salivary to serum biomarkers, using Pearson 
correlation; 
5. The prognostic predictiveness of pre-operative biomarkers using ROC 
curves; 
 
In addition, a multivariate model was used to determine clinical and biomarker 
explanatory variables of treatment outcome. The explanatory variables (potential 
prognostic factors) tested included mainly salivary biomarkers (MMP-8, HNP1-3 
and S100A8) at baseline. The predictive power of these explanatory variables was 
tested using simple and multiple logistic regressions. 
The high correlation among periodontal clinical parameters like probing depth and 
clinical attachment level causes complexity in order to model these parameters. A 
simple logistic regression for every explanatory variable was the first step on 
modelling process. The variable was removed if it did not show statistical 
significance at a liberal 10% level in the univariate analysis. Then all the significant 
variables were included in the final multivariate model to find out the significant 
predictors of treatment response. As multiple regression allows one variable for 
every 10 participants, we had sufficient power to include up to five parameters. 
All statistical analyses were carried out with the supervision of Dr M Andiappan, 
Lecturer in Statistics, KCL Dental Institute, who also carried out the logistic 






A total of 66 participants were recruited, but only 61 were included in the study 
(two participants declined treatment and three participants had less than 20 teeth 
at the time of periodontal assessment .i.e. at the first clinical visit). Whilst the study 
was progressing a further four participants were excluded from the study because 
they had started antibiotic therapy after the second visit. The antibiotics had been 
prescribed by their general medical practitioners to treat systemic and not 
oral/dental infections. However, the periodontal treatment and reassessment for 
these four patients was completed as for every other participant in the study. In 
addition, a further four participants failed to attend the reassessment visit. In total 



























At the 1st visit 
     3 got <20 teeth 






After the 2nd & 3rd 
visits 
4 had antibiotic 
therapy 
At the last visit 




From the subjects who completed the study a total of 129 teeth were missing from 
42 participants at the baseline assessment (after exclusions of all third molars and 
first premolars that were extracted for orthodontic reasons). A further two teeth 
were extracted from two participants after initial assessment and these teeth were 
excluded from further analysis. 
The initial demographic details for the study cohort that completed the study and 
included in the data analysis, are summarised in Table 3-2 . 
 
Age Mean 45.49 SD 8.95 Range 23-65 
Gender Male 28 Female 25  
Smoking Non-smokers 39 Smokers 14  
Diabetes Mellitus  3 (Type II)   
No. of deep sites Mean 33.57 SD 20.75 Range 4-99 
No. of missing teeth Mean 2.43 SD 2.08 Range 0-9 
 
Table 3-2: Demographic data of the participants who completed the study. 
 
We also calculated the sample size required after the completion of the study to 
check our initial assumptions in the power calculation, based on comparing the 
salivary biomarker (MMP-8) levels before and after periodontal treatment using a 
paired sample t-test. The total number required was 21 participants, with 0.66 the 
actual effect size and 100% power using post hoc analysis. 
 
3.3.1  Outcome of clinical parameters 
Using univariate data analysis of the changes in clinical variables following 
periodontal treatment, there was a statistically significant reduction in the means 
of probing pocket depth, number of deep sites (≥ 5mm PPD), plaque and bleeding 
indices. In addition, there was a statistically significant increase in the gingival 










(Mean ± SD) 
After treatment 
(Mean ± SD) 
p value 






Number of Deep Sites 33.57 ± 20.75 18.51 ± 13.87 <0.0001* 
Plaque Index 0.46 ± 0.20 0.37 ± 0.18 0.0003* 




3mm ± 0.91mm <0.0001* 
* Statistically significant (p<0.05). 
Table 3-3: Change in clinical variables after periodontal treatment using 2- tailed 
paired t-test. 
 
3.3.1.1 Individual Patient Responses 
As described earlier, we used the “percentage of non-responding deep sites” as 
our primary outcome measure, where participants were classified accordingly to 
responders and non-responders.  
In order to dichotomize the study participants according to their response to the 
provided treatment, we used a cut-off point of the percentage of non-responding 
deep sites (≥50%). Therefore, all participants that showed an improvement of at 
least 50% or more of their deep sites after treatment, were classified as 
responders and vice versa.  
Applying this cut-off (≥50%) to the results of this study, out of 53 participants there 
were 40 responders and 13 non-responders .i.e. only 24.5% of the chronic 
periodontitis cases did not respond to the non-surgical periodontal treatment 





Figure 3-2: Clustered column chart shows the dichotomised participants 
according to the cut-off (≥50%) of the percentage of non-responding deep sites 
over periodontal treatment.  
 
In addition, in terms of the change in the mean of probing pocket depth after non-
surgical periodontal treatment, most of the cases showed positive change, and 
only three showed overall deterioration after treatment Figure 3-3.  
 
 
Figure 3-3: Clustered column chart shows the change in the mean of probing 



































































There was a strong correlation between both of these clinical outcomes 




































r = - 0.9
p <0.0001
 
Figure 3-4: Scatter plot graph showing the significant correlation (p<0.0001) 
between the percentage of non-responding deep sites and change in PPD. 
 
3.3.1.2  Clinical Parameters in Responders vs. Non-
responders 
The demographic data of the participants was not significantly different between 
responders and non-responders Table 3-4. However, there were statistically 
significant reductions in the change of both probing pocket depth and number of 
deep sites between responders and non-responders. On the other hand, there 
was no statistical significant difference between the two groups in terms of change 
in plaque & bleeding indices and gingival recession. Also, both the number of deep 
sites and probing pocket depth at baseline were not statistically significant 




Variable Responders Non-responders P Value 
Total Number 40 13  













Diabetes  3 0  
*P value by Fishers Exact Test, **P value by unpaired t-test. 





(Mean ± SD) 
Non-responders 
(Mean ± SD) 
p value 















Number of Deep Sites 
(Change) 
17.95 ± 13.39 6.15 ± 4.14 
<0.0031
* 
Number of Deep Sites 
(Baseline) 
34.68 ± 22.70 30.15 ± 13.20 0.5 
Plaque Index 
(Baseline) 
0.46 ± 0.19 0.46 ± 0.22 1 
Plaque Index 
(Change) 
0.09 ± 0.16 0.08 ± 0.17 0.9 
Bleeding Index 
(Baseline) 
0.32 ± 0.18 0.31 ± 0.21 0.8 
Bleeding Index 
(Change) 








* Statistically significant (p<0.05). 
Table 3-5: Comparison of clinical variables in responders versus non-responders 
by 2-tailed unpaired t-test.  
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3.3.2 Clinical Data Intra-examiner Reproducibility  
A total of eight participants were randomly selected in order to re-measure both 
probing pocket depth (PPD) and recession (Rec) of half-mouth (two quadrants), 
at the same visit (either at baseline or reassessment visits). The side selection 
was random; four participants were selected for the right side and four for the left 
side. All the readings were carried out by the same clinical researcher (BK). A total 
of 560 sites were included in the reproducibility study. 
 
3.3.2.1  Using the Means of Probing Pocket Depth & 
Recession 
The correlations between the first and second measurements for (PPD) and (Rec) 
are 0.85 and 0.89 respectively. Both the correlations are statistically significant 
(p<0.0001) indicating the two measurements are linearly related but does not 
necessarily mean that there is a good agreement between the two measurements. 
Hence, a Bland-Altman graph was drawn by taking the mean of the two 
measurements (first and second measurement) and the difference between the 
two measurements. The graphs are shown in Figure 3-5 for PPD and Figure 3-6 
for REC.  From the graph it is clear that there is no systematic difference (fixed 
bias) and all the data points lie below mean + 2 SD. Further analysis of one sample 
t-test to test whether the mean difference is different showed that the mean 
difference is not significantly different (p=0.40 for PPD and p=0.14 for REC) from 
0. This indicates that there is no fixed bias in the measurement.  
Linear regression between mean and difference of the two measurements showed 
that there is no proportional bias between the two measurements (the slope for 
both PPD and REC were not significant). Hence it can be concluded that both the 





Figure 3-5: Bland Altman graph for PPD. 
 
 




3.3.2.2  Using the Actual Individual Readings for Probing 
Pocket Depth & Recession 
As a difference of more than 2 mm is considered to be a significant difference, the 
differences in the PPD and REC values between the two ratings were as below 
Table 3-6 and  
Table 3-7. 
Difference No. of sites % of sites 
0 331 59.1 
1 171 30.5 
2 44 7.9 
>2 14 2.5 
Total 560 100.0 
 




Difference No. of sites % of sites 
0 301 62.3 
1 155 32.1 
2 24 5.0 
>2 3 0.5 
Total 483 100.0 
 
Table 3-7: Shows the recession (REC) difference between the two readings. 
 
From Table 3-6 and Table 3-7, it is clear that the two measurements for PPD and 
REC are ≤ 2 in 97.5% and 99.5% of sites respectively. Hence there is a good intra-
examiner agreement. The mean difference for PPD and REC was 0.55 and 0.44 
respectively, which is much lower than the threshold of 2 and hence we can 
conclude that both ratings are agreeing.  
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3.3.3 Biochemical Parameters  
 
3.3.3.1  Salivary Biomarkers  
The levels of MMP-8 and S100A8 reduced dramatically after the non-surgical 
periodontal treatment Table 3-8, Figure 3-7 and Figure 3-8. Despite the apparent 
reduction in HNP1-3 concentrations after treatment, this reduction did not reach 
statistical significance Table 3-8 and Figure 3-9. 
 
Salivary Biomarker  
Baseline 
(Mean ± SD) 
Review 
(Mean ± SD) 
P value 
MMP-8 (ng/ml) 355.4 ± 319.9 216.6 ± 217.2 <0.0001* 
HNP1-3 (µg/ml) 4.6 ± 6.6 3.4 ± 4.4 0.3 
S100A8 (ng/ml) 1182 ± 1095 693.9 ± 719.6 0.0007* 
 
Table 3-8: Changes in salivary biomarkers following periodontal treatment using 
paired t-test. 
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         * * *p < 0 .0 0 0 1
  
Figure 3-7: Vertical Scatter plot chart showing the significant reduction in MMP-8 
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* * *p = 0 .0 0 0 7
  
Figure 3-8: Vertical scatter plot chart showing the significant change in S100A8 
levels over non-surgical periodontal treatment.  
 



















p = 0 .3
 
Figure 3-9: Vertical scatter plot chart showing the non-significant change in 
HNP1-3 levels over non-surgical periodontal treatment.   
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3.3.3.2  Serum Markers 
Neither CRP nor IL-6 concentration showed any statistically significant reduction 




(Mean ± SD) 
Review 
(Mean ± SD) 
P value 
CRP (mg/L) 4.7 ± 6 4.3 ± 6.5 0.6 
IL-6 (pg/ml) 1.2 ± 1 1.1 ± 0.9 0.7 
 
























p = 0 .6 4
 
Figure 3-10: Vertical scatter plot chart showing a non-significant change in CRP 
levels over non-surgical periodontal treatment.   
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   p = 0 .6 8
 
Figure 3-11: Vertical scatter plot chart showing a non-significant change in IL- 6 
levels over non-surgical periodontal treatment.  
 
A summary of the univariate analyses of clinical and biochemical treatment 
outcomes are shown in Table 3-10: 
Variable 
Before treatment 
(Mean ± SD) 
After treatment 
(Mean ± SD) 
p value 
Probing Pocket Depth 
(mm) 
5.92 ± 0.47 4.74 ± 0.76 <0.0001* 
Number of Deep Sites 33.57 ± 20.75 18.51 ± 13.87 <0.0001* 
Plaque Index 0.46 ± 0.20 0.37 ± 0.18 0.0003* 
Bleeding Index 0.32 ± 0.20 0.21 ± 0.16 <0.0001* 
Gingival Recession 
(mm) 
2.65 ± 0.99 3 ± 0.91 <0.0001* 
MMP-8 (ng/ml) 355.4 ± 319.9 216.6 ± 217.2 <0.0001* 
HNP1-3 (µg/ml) 4.6 ± 6.6 3.4 ± 4.4 0.3 
S100A8 (ng/ml) 1182 ± 1095 693.9 ± 719.6 0.0007* 
CRP (mg/L) 4.7 ± 6 4.3 ± 6.5 0.6 
IL-6 (pg/ml) 1.2 ± 1 1.1 ± 0.9 0.7 
* Statistically significant (p<0.05). 
Table 3-10: Summary of clinical and biochemical changes after periodontal 




3.3.3.3  Biochemical Outcomes in Responders vs. Non-
responders 
 
Before periodontal treatment, only salivary MMP-8 showed a statistically 
significant difference between responders and non-responders at baseline level, 
with responders having a significantly higher baseline concentration of MMP-8 
compared with non-responders Table 3-11 and Figure 3-12 . After treatment, none 
of the tested markers showed any statistical difference between the two groups at 




(Mean ± SD) 
Non-responders 




419.3 ± 343.1 158.8 ± 73.3 0.009* 
MMP-8 Outcome 
(ng/ml) 
238.2 ± 235.2 150.1 ± 135.5 0.2 
HNP1-3 Baseline 
(µg/ml) 
5.0 ± 7.4 3.2 ± 3.0 0.4 
HNP1-3 Outcome 
(µg/ml) 
3.5 ± 4.4 3.2 ± 4.5 0.9 
S100A8 Baseline 
(ng/ml) 
1305 ± 1211 802.2 ± 470.1 0.2 
S100A8 Outcome 
(ng/ml) 
742 ± 726.8 546 ± 703.9 0.4 
CRP Baseline (mg/L) 5.4 ± 6.3 2.6 ± 4.4 0.1 
CRP Outcome (mg/L) 4.9 ± 7.1 2.6 ± 3.7 0.3 
IL-6 Baseline (pg/ml) 1.3 ± 1.1 0.8 ± 0.5 0.1 
IL-6 Outcome (pg/ml) 1.2 ± 0.9 0.9 ± 0.6 0.3 
* Statistically significant (p<0.05). 
Table 3-11: Analysis of the biochemical variables before and after periodontal 







In terms of change in both salivary (MMP-8, HNP1-3 and S100A8) and systemic 
markers (CRP and IL-6), only MMP-8 showed a statistically significant difference 
between responders and non-responders Table 3-12 and Figure 3-13.  The levels 
of HNP1-3, S100A8, CRP and IL-6 did not show any significant difference 





(Mean ± SD) 
Non-responders 




181.1 ± 240.3 8.7 ± 106.1 0.02* 
HNP1-3 Change 
(µg/ml) 
1.5 ± 5.2 -0.1 ± 3.5 0.3 
S100A8 Change 
(ng/ml) 
563 ± 1055 256.3 ± 726 0.3 
CRP Change (mg/L) 0.4 ± 5.8 -0.004 ± 2.3 0.8 
IL-6 Change (pg/ml) 0.1 ±  1 -0.1 ± 0.6 0.5 
* Statistically significant (p<0.05). 
Table 3-12: Changes in biochemical variables in responders versus non-
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Figure 3-12: Column scattered plot graph showing the statistically significant 
difference in the MMP-8 baseline levels between responders and non-responders 
before periodontal treatment. 
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Figure 3-13: Column scattered plot graph showing the statistically significant 
difference in the change of MMP-8 levels between responders and non-




3.3.4  Clinical & Biochemical Outcomes in Smokers vs. Non-
smokers 
As showed earlier, out of 53 participants in this study there were 14 smokers and 
39 non-smokers. The two-tailed unpaired t-test showed no significant difference 
in terms of all clinical and biochemical parameters at baseline level (before 
treatment) Table 3-13 and Table 3-14. 
In terms of changes of these parameters after periodontal treatment, the only 
variable that showed significant difference between the two groups is the change 
in plaque index (PI) in which the PI change was higher in non-smokers than 




(Mean ± SD) 
Smokers 
(Mean ± SD) 
p value 














Number of Deep Sites 
(Baseline) 
34.05 ± 22.63 32.21 ± 14.91 0.8 
Number of Deep Sites 
(Change) 
15.31 ± 13.82 14.36 ± 9.99 0.8 
Plaque Index 
(Baseline) 
0.48± 0.20 0.41 ± 0.18 0.3 
Plaque Index 
(Change) 
0. 11± 0.16 0.002 ± 0.13 0.02* 
Bleeding Index 
(Baseline) 
0.32 ± 0.21 0.31 ± 0.10 0.7 
Bleeding Index 
(Change) 















* Statistically significant (p<0.05). 
Table 3-13: Comparison of baseline and changes in clinical variables in smokers 
versus non-smokers following periodontal treatment, using unpaired t-test (two 






(Mean ± SD) 
Smokers 




354.7 ± 324.2 357.5 ± 319.7 1 
MMP-8 Change 
(ng/ml) 
149.7 ± 229.5 108.7 ± 225.3 0.6 
HNP1-3 Baseline 
(µg/ml) 
5.4 ± 7.4 3.3 ± 2.6 0.1 
HNP1-3 Change 
(µg/ml) 
1.1 ± 5.5 1.1 ± 2.1 1 
S100A8 Baseline 
(ng/ml) 
1273 ± 1252 928.7 ± 348.2 0.3 
S100A8 Change 
(ng/ml) 
492.9 ± 1119 473.4 ± 485.7 0.9 
CRP Baseline (mg/L) 4.6 ± 6.1 4.9 ± 6 0.8 
CRP Change (mg/L) 0.2 ± 5.8 0.7 ± 2.3 0.7 
IL-6 Baseline (pg/ml) 1.2 ± 1 1.2 ± 1 0.8 
IL-6 Change (pg/ml) 0.1 ± 0.9 0 ± 0.9 0.6 
* Statistically significant (p<0.05). 
Table 3-14: Comparison of baseline and changes in biochemical variables before 
and after periodontal treatment in smokers versus non-smokers, using unpaired t-
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Figure 3-14: Column scattered plot graph showing the statistical significance 




3.3.5    Associations 
































* Statistically significant (p<0.05). 
Table 3-15: Linear regression models the relationship between the change in 





Linear regressions were used to model the change of biomarkers and treatment 
outcome between baseline and post-treatment, and the effect of biomarkers and 
demographic variables on treatment outcome.  We used the change in the probing 
pocket depth (PPD) as our treatment outcome indicator (as we showed earlier in 
the results that the probing pocket depths were significantly reduced after 
treatment (p<0.0001)). 
After periodontal treatment, the only biomarker that showed a significant 
association between the change in concentration and the treatment outcome 
(change in probing pocket depth) was MMP-8 Table 3-15 and Figure 3-15. 
However, this relationship was weak.  The change of salivary HNP1-3 & S100A8, 
and serum CRP & IL-6, after treatment, did not show any statistical association 
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Figure 3-15: Scatter plot graph shows the significant association (p=0.02) of 





































* Statistically significant (p<0.05). 
Table 3-16: Linear regression models the relationship between the baseline levels 
of biomarkers and treatment outcome.  
To investigate the prognostic utility of these biomarkers using linear regressions 
again in order to model the association of the baseline levels (before treatment) 
of these biomarkers to the treatment outcome.  
The baseline levels of salivary biomarkers MMP-8 and S100A8 showed a 
statistically significant association with the treatment outcome Table 3-16, Figure 
3-16 and Figure 3-17. However the relationship was weak. The baseline levels of 
salivary HNP1-3 and serum CRP & IL-6, did not show any statistical association 
with treatment outcome Table 3-16. 
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Figure 3-16: Scatter plot graph shows the significant association (p=0.03) of 
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Figure 3-17: Scatter plot graph shows the significant association (p=0.02) of 
treatment outcome to the baseline levels of salivary S100A8. 
 
3.3.6     Prognostic Utility of Salivary/ Systemic Markers 
In order to determine a cut-off point for the prognostic utilities of these markers we 
carried out ROC curve analysis of the markers’ baseline levels of responders 
versus non-responders. From the results of previous analysis MMP-8 was the only 
biomarker that showed a statistically significant difference between the two groups 
at baseline level (before treatment) (*p=0.009). 
ROC curve analysis of the MMP-8 baseline levels in responders versus non-
responders showed that MMP-8 baseline concentration at cut-off point of (<182.8 
ng/ml) can predict the responsiveness to periodontal treatment with 77% 
sensitivity and 70% specificity Figure 3-18. 
Interestingly, if we increase the baseline MMP-8 cut-off to <253.4 ng/ml in order 
to achieve high sensitivity of 92.3%, the specificity remained reasonably high at 
60%. On the other hand, dropping the cut-off to <41.91 ng/ml in order to achieve 
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Figure 3-18: ROC curve construct for salivary MMP-8 baseline levels with 
significant ability to distinguish between responders and non-responders. 
 
 
3.3.7 Salivary Biomarkers vs. Systemic Markers 
(Correlations) 
In order to investigate the relationship between local (salivary) biomarkers and 
systemic (serum) markers, we ran a Pearson correlation statistical analysis to 
check the relationship of both baseline levels and change (baseline level minus 
outcome level) over treatment of these local/systemic markers to each other.   
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* Statistically significant (p<0.05) 
Table 3-17: Pearson correlation table demonstrates the relationship between the 
salivary and systemic markers at baseline level. 
 
As we can see from the results of the above Table 3-17 there was a moderate 
positive correlation between baseline concentrations of salivary MMP-8 & HNP1-
3 Figure 3-19 and between baseline measurements of CRP & IL-6 Figure 3-20. 
No other significant correlations were seen (Pearson correlation, two-tailed p 
value).   
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Figure 3-19: Scatter plot graph showing the significant correlation (p<0.0001) 
between the baseline levels of salivary MMP-8 & HNP1-3. 
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Figure 3-20: Scatter plot graph showing the significant correlation (p=0.0003) 
between the baseline levels of systemic CRP & IL-6.  
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The baseline level correlations of serum CRP to salivary MMP-8 and S100A8 were 
non-significant (Pearson correlation, two-tailed p value) Table 3-17, Figure 3-21 

























Figure 3-21: Scatter plot graph showing the non-significant correlation (p=0.2) 

























Figure 3-22: Scatter plot graph showing the lack of correlation (p=0.4) between the 




3.3.7.2  Correlation between the change in salivary/systemic 
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* Statistically significant (p<0.05) 
Table 3-18: Pearson correlation table demonstrates the relationship between the 
change of salivary and systemic markers after periodontal treatment. 
 
As shown in Table 3-18 there were significant and moderate positive relationships 
in the changes (pre minus post) of salivary MMP-8 & HNP1-3 and of CRP & IL-6 
after non-surgical periodontal treatment:  (Pearson correlation, two-tailed p value) 
Figure 3-23 and Figure 3-25. In addition there was a weak, but significant 
relationship between the changes in salivary MMP-8 & S100A8 (Pearson 
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Figure 3-23: Scatter plot graph showing the significant correlation (p<0.0001) 
between the changes in salivary MMP-8 & HNP1-3. 
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Figure 3-24: Scatter plot graph showing the significant correlation (p=0.04) 
between the changes in salivary MMP-8 & S100A8.  
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Figure 3-25: Scatter plot graph showing the significant correlation (p=0.002) 
between the changes in systemic CRP & IL-6. 
 
3.3.8  Application of Salivary Biomarkers’ pre-determined 
cut-off points into the cohort of this study  
(Validation of Sensitivity Diagnostic) 
In the previous chapter in this thesis, we have shown that salivary MMP-8, HNP1-
3 and S100A8, individually and as a composite biomarker, had the ability to 
differentiate between gingivitis and chronic periodontitis.  
The data from this study here was an opportunity to re-validate the ability of these 
salivary biomarkers (MMP-8, HNP1-3, and S100A8) to detect periodontal disease 
in the cohort of this study. Due to the fact that only subjects with chronic 
periodontitis were recruited in this study, we only can test sensitivity and not 
specificity of these predetermined cut-offs. Within this cohort of subjects, the 
application of the predetermined cut-off points for MMP-8 (>82.73 ng/ml), HNP1-
3 (>3.745 µg/ml), and S100A8 (>191.3 ng/ml) at baseline detected periodontitis 
with sensitivity of 85%, 64.1% and 90.6% respectively.  
Interestingly, when we combine the three salivary biomarkers (after normalizing 
each marker to its’ pre-determined cut-off point), and we applied the composite 
marker predetermined cut-off (MMP-8+HNP1-3+S100A8) (>2.570) the sensitivity 
improved dramatically to 94.3%.  
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3.3.9  Predictors of Treatment Response  
As explained before, the participants in this study were classified into responders 
and non-responders, based on the percentage of non-responding deep sites. A 
separate simple logistic regression was used to find out whether any of the study 
variables (explanatory variables) including age, sex, smoking, medical health, 
ethnicity, follow up time (in weeks), baseline bleeding index, baseline plaque index 
and the baseline biomarkers levels (MMP8, HNP1-3, S100A8, CRP and IL-6) 
predict the response status. In order to increase the power of the analysis, only 
predictor variables that were significant at a liberal 10% level in the individual 
logistic model fitted for each potential predictor variables separately were included 
in the final multivariate logistic model that aimed to find out the significant 






95% CI for 
OR 
 
LCL        UCL 
P value 
Age -0.02 (1.02) 0.95 1.09 0.68 
Gender (1.06) 0.30 3.71 0.93 
Ethnicity (1.43) 0.40 5.06 0.58 
Medical Health (0.49) 0.13 1.86 0.30 
Smoking  (0.74) 0.17 3.20 0.68 
Reviewed in 
weeks 
-0.10 (0.90) 0.71 1.16 0.42 
Baseline PPD -0.50 (0.61) 0.16 2.36 0.47 
No. deep sites -0.01 (0.99) 0.96 1.02 0.49 
Baseline BI -0.43 (0.65) 0.02 19.87 0.80 
Baseline PI -0.007(0.99) 0.04 23.97 0.99 
Baseline MMP-8 -0.006(0.99) 0.99 1.00 0.03* 
Baseline HNP1-3 -0.09 (0.92) 0.75 1.12 0.39 
Baseline S100A8 -0.001 (0.99) 0.99 1.00 0.08 
Baseline CRP -0.13 (0.88) 0.73 1.06 0.17 
Baseline IL-6 -0.79 (0.45) 0.16 1.26 0.13 
PPD=Probing Pocket Depth, BI=Bleeding Index, PI=Plaque Index 
* Statistically significant (p<0.05). 






The results showed that only MMP-8 and S100A8 were significantly predicting the 
response status at 10% level. Therefore, further analysis was carried out by 
including MMP-8 and S100A8 as predictor variables and response status as 
outcome variable in the final multivariate logistic model. 
The final analysis showed that both salivary MMP8 and S100A8 did not 
significantly predict the response status. However, in the individual model MMP8 






95% CI for 
OR 
 
LCL        UCL 
P value 
MMP-8 Baseline -0.005 (0.99) 0.99 1.00 0.08 
S100A8 Baseline 0.00 (1.00) 0.99 1.00 0.66 
 




3.4 Discussion  
 
The main purpose of this longitudinal interventional study was to investigate the 
prognostic utility of group of biomarkers that have been identified as potential 
biomarkers for the diagnosis of periodontal disease. It would be of great interest 
to many dental clinicians to find a tool that helps them identify patient’s response 
to treatment beforehand, as this might be useful for treatment planning decisions 
and could conceivably influence selection of whether adjunctive therapeutic 
treatment, such as locally or systemic delivered antibiotics, are needed or not. 
Therefore, this prognostic test could improve and speed the quality of care to the 
patient as well as avoiding unnecessary over and under treatment.   
The clinical results in this longitudinal study are in harmony with the overwhelming 
evidence that non-surgical periodontal treatment is effective in the management 
of periodontal disease and most patients response reasonably well to this 
treatment (Badersten et al., 1984; Badersten et al., 1981; Cobb, 1996; Hill et al., 
1981; Hujoel et al., 2000; Lindhe et al., 1982; Pihlstrom et al., 1983; Van der 
Weijden and Timmerman, 2002).  
Similar to Hughes and co-workers’ longitudinal study, we used the percentage of 
non-responding deep sites as our primary outcome measure in this study, where 
participants were classified accordingly to responders and non-responders after 
treatment. The difference that we used (≥50%) cut-off instead of (≥30%) (Hughes 
et al., 2006b). As this cut-off (50%) suits this study data more in which it is in line 
with the results of many traditional studies that divided the response of periodontal 
patients after treatment into three categories: the majority (about 60_80%) 
respond extremely well to treatment, a second group (about 12-28%) continue to 
lose teeth after treatment (progressive PD), and a third group (about 4-10%) of 
patients are considered to have an ‘extreme downhill’ response to treatment 
(Goldman et al., 1986; Hirschfeld and Wasserman, 1978; McFall Jr, 1982). In this 
study, there were only 24.5% of the cases that were classified as not responding 
to the treatment. In addition, there were statistical significant reductions in the 
change of both probing pocket depth and number of deep sites, between 
responders and non-responders. 
After non-surgical periodontal treatment, the salivary biomarkers MMP-8 and 
S100A8 concentrations reduced dramatically, While HNP1-3 did not show any 
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significant reduction. However, our finding of reduction of MMP-8 levels after 
periodontal treatment was similar to other studies (Kinane et al., 2003; Marcaccini 
et al., 2009b; Sexton et al., 2011). In addition, there was a significant association 
between both the baseline levels and change of MMP-8 and the clinical outcome 
indicator (PPD change) which is in line with other studies’ findings (Chen et al., 
2000; Kraft-Neumarker et al., 2012), while for S100A8 our data contradicted the 
results of Haigh and co-workers’ study which concluded that S100A8 & A9 
increased after treatment of periodontal disease (Haigh et al., 2010). 
As well as analysing the data by the dichotomised outcome of “responders” vs 
“non-responders” we also investigated the correlation of biomarkers with the 
continuous outcome variable of change in pocket depth.  These results gave 
similar findings to those of the primary outcome, with both MMP-8 and S100A8 
being significantly but only weakly correlated with change in pocket depth. 
Interestingly, MMP-8 is the only biomarker that showed a statistical difference 
between responders and non-responders, in both baseline levels preoperatively 
and changes in its concentrations postoperatively. This finding is in agreeing with 
Sexton and co-workers’ six months case-control study in which they found MMP-
8 is the best biomarker for demonstrating response to non-surgical periodontal 
therapy (Sexton et al., 2011). Surprisingly, the mean baseline and change in 
concentrations of MMP-8 were significantly higher in responders than non-
responders, which indicate that the higher MMP-8 levels at baseline the better 
expected response to treatment. However, low levels MMP-8 (< 182.8 ng/ml) do 
not necessarily indicate poor response. 
In terms of predicting treatment outcome of periodontal disease, none of the 
clinical parameters showed any predictive ability of treatment outcome which is in 
line with the results of studies (Hughes et al., 2006b; Persson et al., 2003). 
Biochemically, only MMP-8 showed prognostic ability and was able to predict the 
responsiveness to periodontal treatment with moderate sensitivity and specificity. 
Although this finding requires further validation, it gives some hope that such a 
periodontal biomarker with both potential diagnostic and prognostic abilities could 
be of help in dental settings to prioritise patients for treatment, tailor a treatment 
plan for every patient and also help in epidemiological screening for periodontal 
disease.  This finding supports the suggestion that MMP-8 may be useful as a 




In this study cohort, we did not exclude smokers and diabetics and we had 3 
diabetic and 14 smokers, out of 53 participants that were included in the study. 
Interestingly, all the diabetic and 11 smokers did respond well to the treatment 
and were assigned as responders. We previously showed that the higher MMP-8 
baseline levels the better the response to treatment and because the majority of 
smokers were responders (11 out of 14) therefore, this finding applies to smoking 
responders as well. This contradicts the findings of Leppilahti and co-workers that 
smokers with elevated levels of MMP-8 at baseline predict a poor treatment 
response (Leppilahti et al., 2014). Despite the small number of smokers, their 
generally good response to periodontal treatment was not expected due to the 
fact the smoking is a major risk factor for periodontal disease, and the negative 
effect of smoking on all aspects of periodontal treatment is confirmed and 
established in the literature (Anner et al., 2010; D'Aiuto et al., 2005c; Grossi et al., 
1996; Heasman et al., 2006; Hughes et al., 2006a; Kinane and Chestnutt, 2000; 
Palmer et al., 1999; Preber and Bergström, 1986; Tonetti et al., 1995). 
In addition, there was no significant difference between smokers and non-smokers 
in terms of all the clinical and biochemical outcomes apart from the change in PI 
in which smokers showed significantly less PI change than non-smokers. The 
logical explanation for these unexpected clinical/ biochemical outcomes for 
smokers is the small sample size (only 14 out of 53), the large number of factors 
(variables) included and the marked biological variability between individuals.  
The biochemical findings were also potentially in contrast to many studies such 
as that of Ohsawa and co-workers which reported that CRP levels were higher in 
smokers than non-smokers and tend to decrease following long-term smoking 
cessation (≥ 5 years) (Ohsawa et al., 2005). Furthermore, a previous study has 
found that MMP-8 levels were higher in smokers than non-smokers, due to the 
fact that smoking modulates the MMP-8 expression in periodontal tissues (Liu et 
al., 2006). On the other hand, many other studies have reported that tobacco 
smoking has been related to lower oral fluid MMP-8 concentrations compared with 
non-smokers with chronic periodontitis (Ding et al., 1994; Heikkinen et al., 2010; 
Mäntylä et al., 2006; Özçaka et al., 2011).  
Non-surgical periodontal therapy has been used in many studies as a reliable 
model to study systemic inflammation (D'Aiuto et al., 2005b, 2007; D’Aiuto et al., 
2004). Many studies have shown that intensive (with adjunctive local antibiotics) 
and successful periodontal therapy results in greater reductions in both local and 
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systemic inflammation than standard periodontal therapy (Artese et al., 2015; 
D'Aiuto et al., 2005a; D'Aiuto et al., 2006; D’Aiuto et al., 2004), particularly a 
significant reduction of the inflammatory systemic markers CRP & IL-6, and 
therefore may reduce CRP- associated cardiovascular risk (D'Aiuto et al., 2004; 
D’Aiuto et al., 2004; Marcaccini et al., 2009a; Mattila et al., 2002), and CRP level 
is directly associated with the periodontal status of an individual (Pederson et al., 
1995). However, our study results showed no significant change of serum IL-6 
after periodontal treatment, which was in agreement with D’Auito & co-workers’ 
results that IL-6 only reduced in the group that received intensive and not standard 
treatment (D'Aiuto et al., 2005a), and another Japanese study (Yamazaki et al., 
2005).   
Another intervention study by Marcaccini and co-workers included cohorts of 20 
controls and 25 chronic periodontitis subjects in order to investigate the difference 
in systemic IL-6 & CRP levels between these cohorts, as well as investigating the 
change in serum levels of IL-6 and CRP three months after non-surgical 
periodontal treatment. Interestingly they concluded that only IL-6 levels were 
significantly higher in diseased than control group, while both systemic markers 
reduced significantly after treatment (Marcaccini et al., 2009a). Similar findings 
were shown in a later interventional study that included 78 subjects with chronic 
periodontitis and 40 healthy controls and they found that both CRP & IL-6 were 
significantly higher in diseased group than controls. Also, the periodontal 
treatment provided involved non-surgical, surgical as well as antibiotics were 
prescribed after the surgery. Therefore, the result of the significant reduction of 
CRP & IL-6 three months after treatment might be largely due to administration of 
antibiotics (Nakajima et al., 2010). 
On the other hand, others, including this study, showed that there was no 
significant change of serum markers after non-surgical periodontal treatment of 
periodontitis (Michalowicz et al., 2009; Tüter et al., 2007), as well as that these 
markers are not good predictors for periodontal disease progression. In addition, 
a systematic review and meta-analysis by Ioannidou and co-workers of the effect 
of periodontal treatment on serum CRP levels concluded that it is very unlikely 
that CRP levels can be reduced by a single round of non-surgical periodontal 
treatment especially in severe periodontal inflammation (Ioannidou et al., 2006). 
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These contradicting results, regarding the change of serum markers after 
periodontal treatment, of many interventional studied might be attributed to many 
factors such as: 
1. The modalities of periodontal treatment used (Standard, Intensive with 
antibiotics, surgical) 
2. The time elapsed since the treatment to measure these markers 
(Immediate, 1 month, 2months…etc), 
3.  The techniques used to measure the markers concentration (ELISA,    
Nephelometry, radial immunodiffusion assay, immunoturbidimetrics). 
4. Whether the potential confounding factors were controlled or not (Smoking, 
age, gender, race...etc). 
However, in the recent consensus report EFP/AAP workshop of periodontitis and 
systemic disease they concluded that the evidence showing periodontal treatment 
reduces CRP levels is not strong enough, and future well-designed intervention 
trials are still needed (Tonetti and Dyke, 2013). 
Regarding the relationship between both salivary and systemic markers 
preoperatively, there was a significant positive moderate relationship between 
salivary MMP-8 & HNP1-3 as well as between serum CRP & IL-6. Postoperatively, 
there were significant positive moderate relationships in the change of levels of 
salivary MMP-8 & HNP1-3 and serum CRP & IL-6, as well as a significant positive 
weak relationship in the change in levels of salivary MMP-8 & S100A8.  Thus the 
local salivary biomarkers showed a weak association with each other, as did the 
systemic markers with each other also. 
This finding of significant correlation between CRP and IL-6 concentrations was 
in harmony with some other studies’ findings (Ide et al., 2003; Loos et al., 2000; 
Ridker et al., 2000), but unlike the results reported by Ide and co-workers’ finding 
(Ide et al., 2004). 
Interestingly, there were no correlations between local and systemic markers in 
this study, which means that the levels of salivary biomarkers are not associated 
with serum markers and both sets of biomarkers are independent from each other. 
Therefore, the salivary biomarkers tested here were not useful as surrogate 
markers of systemic inflammation.  
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3.5  Conclusions  
 
This interventional study has concluded that none of the clinical parameters show 
the ability to predict treatment outcome. On the other hand, the salivary 
biomarkers MMP-8 & S100A8 showed some promising periodontal prognostic 
ability to detect a likely good response to treatment, with MMP-8 showing the best 
results with moderate sensitivity and specificity. The interesting finding in the 
results of this study was that the higher MMP-8 concentrations before treatment 
the better response predicted. However, this test might be useful to detect likely 
good responses, but not at detecting poor responses, which would be a much 
more useful result clinically. In addition, a single round of standard non-surgical 
periodontal treatment had no effect on the systemic markers levels CRP & IL-6, 
and there were no correlation between salivary and systemic markers. 
Therefore, these results give some hope for the use of salivary analysis as a 
treatment predictor of periodontal disease although the ability to detect likely  poor 
responders might clinically be of more use than being able to predict good 
responses.  Further studies would be valuable to test other biomarkers both 
separately and in combinations. The absence of any clear both clinical or 
biochemical prognostic marker of poor responses is consistent with other previous 
studies and emphasises the likely complexity of factors which are responsible for 













4. Final Discussion, Future Work and Conclusion 
 
4.1 Final Discussion 
 
The studies described in this thesis were carried out in order to investigate the 
potential role of specific salivary biomarkers as diagnostic and prognostic markers 
of periodontal disease.  In particular, following previous studies in our lab that had 
identified three antimicrobial peptides, HNP1-3, LL-37 and S100A8 with diagnostic 
periodontal potential, we tested their potential utility as biomarkers, and 
additionally compared their performance with salivary MMP-8 concentrations.   In 
a newly recruited cohort of patients of specified periodontal diagnoses, we showed 
that MMP-8, HNP1-3 and S100A8, but not LL-37, all were able to discriminate 
between gingivitis and chronic periodontitis with over 90% specificity and good 
sensitivity.  Combining the results of these individual tests, particularly by the 
normalised data method described in Chapter 2 gave further improvements in the 
diagnostic accuracy of these tests.  From these results we were able to define cut-
off points for a positive test and apply these to a validation study carried out on 
samples from an independent cohort of subjects. 
The samples for the validation study on the independent cohort were from a study 
investigating the effect of diabetes on periodontal disease carried out at the 
University of Glasgow (Hodge et al., 2012).  This cohort included non-diabetic, 
well controlled and poorly controlled type I diabetic patients.  In general these 
subjects had relatively low levels of periodontal disease, particularly in the non-
diabetic subjects, and represented a challenging cohort for the diagnostic tests. 
In general our biomarker tests performed much less well in the validation study, 
with biomarkers continuing to show reasonable specificity but with very low 
sensitivity.  Furthermore we found that diabetes influenced the levels of MMP-8 
and possibly S100A8 which suggests that these diagnostic tests would not be 
suitable for use on patients with Diabetes. 
Interestingly, when we applied our pre-chosen diagnostic cut-off points to the 
prognostic study cohort of this study at the baseline of that study (included only 
cases with CP), both MMP-8 and S100A8 showed high sensitivity whilst the 
sensitivity for HNP1-3 was moderate. In the absence of a gingivitis group in the 
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prognosis study we were unable to assess specificity. In addition, in a relatively 
small unpublished study by Dr. F.Saleh in our laboratory (N = 35) investigating the 
correlation between HNP1-3 levels and the number of PMNs, he applied our 
HNP1-3 diagnostic cut-off to his study cohort (which included cases with G & CP) 
and it showed that this cut-off could differentiate gingivitis from chronic 
periodontitis with 100% specificity and 57% sensitivity.  
These later observations from secondary analyses are much more encouraging 
than the results from our Glasgow cohort study and do encourage us to consider 
further validation studies in larger, non-diabetic cohorts. 
It is noteworthy that using the cut-off points derived from our initial study tends to 
give much better specificity than sensitivity.  It is debateable whether a periodontal 
diagnostic test should err on the side of specificity rather than sensitivity and would 
rather depend on the specific application that the test might be applied to.  For 
example, a specific test would likely be of considerable use in large 
epidemiological studies to allow the identification of a sub-cohort with periodontitis 
with high certainty, but a very insensitive test might be of limited value as a 
diagnostic test for (eg) self-monitoring or diagnosis in non-dental settings such as 
physician’s clinics. 
Predicting the progression of periodontal disease and assessing its likely 
response to treatment has been a focus of periodontal research for years. Clinical 
and radiographical parameters that clinicians use to assess periodontal disease 
have little predictive ability and largely provide information about the history of the 
disease. In our longitudinal prognostic study, we were able to confirm that the 
clinical parameters such as PI, BI, PPD...etc, are poor predictors of periodontal 
treatment outcome.  
The levels of salivary biomarkers MMP-8 and S100A8 both reduced significantly 
after periodontal treatment.  Reductions in salivary biomarkers following treatment 
might be useful for longitudinal monitoring of disease status, particularly 
conceivably when applied as longitudinal self-monitoring by patients of their own 
condition in a home care setting.  However all the biomarkers tested were unable 
to identify subjects who subsequently responded poorly to treatment.  Interestingly 
those subjects with high baseline MMP-8 levels showed a good response to 
treatment.  The biological reasons for this effect are not at all clear but it is possible 
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to speculate that those with an existing robust inflammatory response are also 
most likely to respond well to treatment. 
The systemic factors CRP and IL-6 did not change in response to treatment.  In 
addition local salivary biomarkers showed no correlation with the systemic factors 
studied. However, interpreting the results of the studies investigating the link 
between PD and systemic disease should be done with caution due to study 
heterogeneity and different periodontal case definitions used. 
There was a modest but significant correlation between salivary levels of MMP-8 
and HNP1-3, in both baseline (pre-operative) and change (post-operative) levels, 
which may be attributed to the fact that both biomarkers are mainly produced by 
PMNs.  However the modest correlation only suggests that these biomarkers are 
not a close surrogate measure of PMN numbers and their production are 
differentially regulated by a range of mechanisms.  Similarly, the systemic factors 
CRP & IL-6 also showed a significant but modest correlation.  The absence of 
close correlations between biomarkers and treatment outcomes probably 
underlines the complexity of the factors which may determine outcomes. 
Along with the advances in molecular biology the interest toward the potential use 
of oral biomarkers (from GCF, saliva or gingival tissue) as tools for point-of-care 
(POC) in periodontal diagnostics and prognostics has soared. Saliva has been 
proposed as the most useful sample to use for periodontal monitoring due to the 
fact that it is unlike blood or GCF in terms of: 
1. Easy, rapid, safe and non-invasive, cost-efficient way of collection for 
disease screening without the need for highly trained professionals.  
2. Simple processing and analysis required. 
3. Salivary analytes are very stable which make it feasible to be collected by 
patients at home and posted to the laboratory. 
It has also been reported that most of salivary analytes do not have marked 
clinically important cyclical rhythm (Fraser, 2001), and are relatively stable if 
stored for many hours at room temperature as well as throughout repeated 
freezing-thaw cycles (Unpublished study by J.Tebbutt).  
The vast majority of longitudinal studies in periodontal biomarker research have 
focussed on monitoring the change of serum markers or GCF biomarkers over 
period of time. Longitudinal changes in salivary biomarkers have been reported 
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far less frequently.  However investigating salivary analytes in relation to 
periodontal disease may be more promising and reflective of the overall oral status 
of an individual rather than the site-specific view the GCF supplies. In addition, 
the salivary proteome may reflect the GCF proteome with higher information 
content for biomarker discovery of periodontal disease and that may be why the 
predictability of biomarker detection in saliva is more than GCF. However, salivary 
biomarkers are probably not a direct surrogate measurement for GCF biomarkers 
as salivary concentrations may vary both with local concentrations of GCF 
analytes, but also may be affected by the extent of local inflammation which would 
result in increased GCF production.  
Collectively, of all the biomarkers tested for both diagnostic and prognostic uses, 
MMP-8 appeared to be superior to the other markers tested. This is consistent 
with previous studies and has led to the development of Point of Care (POC) 
devices for assessing MMP-8 (Kinney et al., 2011; Sorsa et al., 2014; Sorsa et al., 
2010; Sorsa et al., 2011). Indeed there are two chair-side MMP-8 testing devices 
that have now been developed for MMP-8: 
1. Dip stick test which provides the result in 5 minutes (Mäntylä et al., 2006; 
Mäntylä et al., 2003). 
2. Dento-analyzer device which applies a sandwich-based immunoassay 
system, and provide result in 15 minutes (Munjal et al., 2007). 
Obviously, as we are still in the process of identification and validation of the 
“Golden Marker(s)” with diagnostic and prognostic ability that are very reliable, 






           4.2 Future Work 
 
Overall the results of both our diagnostic and prognostic studies are encouraging, 
but do not validate the biomarkers tested sufficiently to suggest translational 
studies to bring these tests to the chairside.  Further studies are required 
particularly improve the reliability of the tests and demonstrate their utility. 
For the diagnostic testing a further large study of validity would be very useful 
given the findings of our validation study, on subjects of known diabetic status and 
a reasonable prevalence of a range of periodontal disease diagnoses.  With this 
in mind, there is a large cross-sectional study about to start within the Department 
which aims to recruit 200 participants from the Twins UK cohort based at Kings 
College London. This study will assess the accuracy of self-reported periodontal 
disease by questionnaire and will supplement this with salivary biomarker testing.  
Unfortunately this study is outside the timescale of this PhD project but will allow 
definitive validation and explore the scope for combining self –reported 
periodontal disease data with additional biomarker testing within a cohort who has 
been extensively phenotyped for medical and behavioural factors. 
To improve the reliability of the current tests it would also be possible to carry out 
further proteomic analysis of collected samples to try to identify additional 
biomarkers present in saliva by mass spectrometry.  In addition it would be useful 
to investigate these markers in the presence of other disease modifying factors, 
most notably smoking, which was excluded from the current studies described 
here.  It might will be that a multifactorial model including salivary biomarkers and 
other parameters may have better accuracy than the result of a salivary test alone. 
The results of the intervention study described in Chapter 3 seem less 
encouraging than our diagnostic study for identifying biomarkers that may predict 
prognosis. In this interventional study we also had the chance to collect plaque 
samples from deep sites (PPD >4mm) before and after (progressive/non-
responding sites) treatment. It would be of great interest to investigate these 
microbial biomarkers change over periodontal treatment, which might give an 
additional predictor biomarkers beside salivary/GCF ones. 
In the longer term, assuming we can improve the reliability of our tests, it would 
be useful to collaborate within a multidisciplinary team to develop POC diagnostics 






In conclusion, the aim of developing salivary diagnostics remains an important 
goal which offers a number of potential applications which have been discussed 
in Chapter 1.  Our studies evaluated the use of 3 novel potential salivary 
biomarkers, the AMPs HNP1-3, S100A8 and LL-37 together with the described 
marker MMP-8.   The results are encouraging in demonstrating the potential utility 
of MMP-8, HNP1-3 and S100A8 but further work is required particularly to improve 
the sensitivity of diagnostic applications and to explore further combining these 
results with additional parameters. Biomarkers that give useful prognostic 
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6.  Appendices  
6.1 Chapter 2: Verification and validation of salivary 
biomarkers as diagnostic periodontal biomarkers 
 
6.1.1 Salivary ELISA Protocols 
 
6.1.1.1 HNP1-3 
All the reagents were brought to room temperature (20-25 ͦ C) before use. Both 
the test and control samples for saliva were diluted at an optimized dilution factor 
of x 5000 .100µl of standard and samples were applied into appropriate wells in 
duplicate in a 96 well plate pre-coated with antibody. The plate was incubated for 
1 hour at room temperature before the solutions were carefully emptied by 
inverting plate and shaking contents out then dried by tapping on a thick layer of 
tissues. Approximately 300µl of wash buffer was added to each well and kept for 
20 seconds before emptying as above. The washing process was repeated for 3 
times. Then 100µl of reconstituted biotinylated tracer antibody was added to each 
well using the same pipetting order as applied in previous steps and again 
incubated for 1 hour at room temperature. Washing was done as described above 
before 100µ of diluted streptavidin-peroxidase was added to each well and 
incubated for 1 hour at room temperature. Washing as above was repeated and 
100µl of TMB substrate added to each well and incubated for 20-30 minutes at 
room temperature in darkness. The reaction was stopped by adding 100µl of stop 
solution (oxalic acid) and the plates read immediately at 450 nm using a plate 
reader (Optima BMG LABTECH. Germany). 
 
6.1.1.2 S100A8 
All the reagents were brought to room temperature (20-25 ͦC) before use. Both the 
test and control samples for saliva were diluted at an optimized dilution factor of 
x100 S100A8 (with second reading of the plates at 405nm for high concentration 









Add 100 μL of diluted samples to the wells 
                                                                           Incubate for 1 hour at room temp. 
Wash the wells 
 
Add 100 μL of HRP conjugated anti-human S100A8/MRP8 antibody 
                                                                           Incubate for 1 hour at room temp. 
Wash the wells 
 
Add 100 μL of Substrate Reagent 
 
Add 100 μL of Stop Solution 
 
Measure absorbance at 450 nm 
 
Optical density of the plates was read immediately at 450 nm using a plate reader 
(Optima BMG LABTECH.Germany). 
 
6.1.1.3 LL-37 
All the reagents were brought to room temperature (20-25 ͦ C) before use. Both 
the test and control samples for saliva were diluted at an optimised dilution factor 
of x 5. All the steps were performed at room temperature and all samples and 
standards done in duplicate in an antibody pre-coated 96 well plate following the 
protocol represented in the schematic drawing below Figure 5-1 according to 
manufacturer`s instructions. Optical density of the plates was read immediately at 






Figure 5-1: Schematic drawing of LL-37 Protocol, adopted from HK321 product 
information and manual of LL-37 (Hycult Biotech). 
 
             6.1.1.4 MMP-8 
All the reagents were brought to room temperature (20-25 ͦ C) before use. First 
the plate was prepared the day before by coating the 96-well microplate with 100µl 
per well of the diluted Capture Antibody (Dilution Factor 1:180), the plate was 
sealed and incubated at room temperature overnight. Then the plate was 
aspirated by inverting plate and shaking contents out then dried by tapping on a 
thick layer of tissues and washed by 400µl of wash buffer using a squirt bottle. 
The wash buffer was kept for 20 seconds before emptying. The washing process 
was repeated for a total of 3 times. Then the plate was blocked by adding 300µl 
of Reagent Diluent (1mg BSA in 100ml PBS) to each well and incubated at room   
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temperature for a minimum of 1 hour. The plate was washed as before. Both the 
test and control samples for saliva were diluted at an optimized dilution factor of x 
300 .100µl of standard and samples were applied into appropriate wells in 
duplicate in a 96 well plate pre-coated with antibody. The plate was incubated for 
2 hour at room temperature, and then the plate was washed as before. 100µl of 
the diluted Detection Antibody (Dilution Factor 1:180) diluted in NGS (Dilution 
Factor 1:40) was added to each well using the same pipetting order as applied in 
previous steps and again incubated for 2 hour at room temperature. Washing was 
done as described above before. 100µ of diluted streptavidin-peroxidase (Dilution 
Factor 1:200) was added to each well and incubated for 20 minutes at room 
temperature away from direct light. Washing as above was repeated and 100µl 
substrate solution added to each well and incubated for 20 minutes at room 
temperature away from direct light. The reaction was stopped by adding 50µl of 
stop solution and the plates read immediately at 450 nm using a plate reader 















6.2 Chapter 3: Prognostic Biomarkers of Periodontal 
Disease 
6.2.1 Volunteer Information Sheet 
 
    
                                                   
 
VOLUNTEER INFORMATION SHEET 
Prognostic Biomarkers of Periodontal Disease 
You are being invited to take part in a study of gum health. Before you decide it is 
important for you to understand why the study is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would 
like more information. Take time to decide whether or not you wish to take part. 
Thank you for reading this. 
1. What is the purpose of the study? 
The purpose of the study is to investigate for specific proteins within the blood and 
saliva that can help in the diagnosis and prediction the outcome of gum diseases. 
This would allow us to develop a new test to monitor patients’ gum health, and 
may also tell us more about the disease processes going on in gum diseases 
2. Why have I been invited? 
You have been invited because you fit the entry criteria of being between 30 – 65 




- be free from any medical or dental conditions that may affect your own safety 
and well-being or that of the study staff as a result of your participation, or that 
may invalidate the study results; 
- possess at least 20 natural teeth 
- Have signs of gum disease to fit one of the different disease categories we want 
to test. These include signs of destructive gum disease, moderate to severe gum 
disease,  
We aim to recruit up to 100 people to take part in this study. 
3. Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part 
you will be asked to sign a consent form. You will be given a copy of this 
information sheet and signed consent form to keep. If you decide to take part you 
are still free to withdraw at any time and without giving a reason. If you do wish to 
withdraw from the study we will remove your records from the study and destroy 
the samples we have taken from you. A decision to withdraw at any time or a 
decision not to take part will not affect the standard of care you receive. 
4. What will happen to me if I take part? 
If you decide to take part in the study you will get the chance to be treated by an 
experienced periodontist. Samples of saliva, blood and plaque will be collected 
from you before and after the gum treatment. 
5. What are the possible disadvantages and risks of taking part? 
There will be no anticipated risks to your health or well-being from participating in 
this study. All procedures and assessments will be carried out by experienced and 
appropriately qualified personnel. Sample of saliva is entirely painless and should 
take about 5 minutes in total to carry out. Taking a blood sample will involve slight 
discomfort from the needle and will take a further 5-10 minutes. Plaque sample 
collection is painless as well and will take less than 1 min. The gum treatment will 
be carried under local anaesthesia. 
6. What are the possible benefits of taking part? 
There are no direct benefits to you in taking part in the study apart from getting 
the initial gum treatment by an experienced periodontist.   
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7. How long will my gum treatment take?  
Basically there will be four clinical sessions. The first one is for thorough gum 
examination assessment. The second and third sessions are for deep cleaning of 
your gums. The last session is for reassessment of your gum response to the 
provided treatment. 
8. What will happen to the samples taken of my saliva, blood and plaque? 
The samples will be stored in a secure freezer in our research laboratories, and 
then will be biochemically analysed in our laboratory to test for the presence and 
concentration of factors known to be produced during inflammation. At the end of 
the study any remaining samples will be stored and may be used for additional 
tests of biochemical present in them. The samples we take should be regarded as 
a gift to the Institution and you will not have any commercial rights over them in 
the unlikely event that they result in the development of a commercial product or 
test. 
9. Who is organising and funding the research? 
The co-sponsors of this study are Kings College London and Guys & St Thomas’ 
Foundation NHS Trust. The study is being carried out by the research team at 
Kings College London Dental Institute. More specifically, the research will be 
carried out by Professor F Hughes and his research team. 
10. What if something goes wrong? 
Although we do not anticipate that there will be any complications, the sponsors 
have agreed that if you are harmed as a result of your participation in the study, 
you will be compensated, provided that, on the balance of probabilities, an injury 
was caused as a direct result of the intervention or procedures you received during 
the course of the study. These special compensation arrangements apply where 
an injury is caused to you that would not have occurred if you were not in the trial. 
These arrangements do not affect your right to pursue a claim through legal action. 
In the unlikely event that you do experience any unusual symptoms please report 
this immediately to Professor Hughes on 020 71884945 or 07714 336 296.  
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11. What will happen to the results of the research study? 
The results of this study will be analysed and we expect to publish the results in a 
dental research journal. A summary of any published results will be placed on the 
department’s web site. 
12. Will my taking part in this study be kept confidential? 
The information we collect from you in the study will be kept confidential and we 
will analyse samples anonymously. 
If you consent to take part in this study any of your records, medical or non-
medical, may be inspected by the sponsors of the study for the purpose of 
reviewing compliance with research protocols. 
13. Who has reviewed the study? 
This study has been reviewed and approved by Newcastle and North Tyneside 2 
on 21st March 2012, ref number 12/NE/0122. 
14. Contact for Further Information. 
Should you have any questions or concerns regarding your participation in this 
study you may contact: 
Professor Francis Hughes 
Professor of Periodontology 
Dental Institute 
Kings College London 
Floor 21 Tower Wing 
Guys Hospital 
Great Maze Pond 
London SE1 9RT 
Tel +44 (0)20 7188 4945 
Fax +44(0) 20 7188 4188 





If you agree to participate in this study you will be given a copy of this information 
sheet and a signed consent form to keep. 























6.2.2 Consent Form 
 
CONSENT FORM 
Prognostic Biomarkers of Periodontal Disease 
  Please 
initial box 
1. I confirm that I have read and understood the Volunteer Information Sheet 
version 2 dated 17th Feb 2012 for the above study and have had the 
opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal 
rights being affected. 
 
3. I understand that my dental notes may be looked at by study monitor(s), the 
auditor(s), the Independent Ethics Committee and the regulatory authorities 
where it is relevant to my taking part in research.  I give permission for these 
individuals to have direct access to my records. 
 
4. I understand that the samples that I have given may be stored at the end of 
this study and may be used for additional tests in the future. 
 
5. I agree to take part in the above study.  
 
Subject’s name (printed)  Subject’s signature  Date  
 
 
     
      









 6.2.3 Clinical Study Report Form 
 
 
Case Report Form 
Study Name: Prognostic Biomarkers of Periodontal Disease 






Gender Male □                    Female □ 
Date of Birth _ _/_ _/_ _ _ _ (Day/Month/Year) 
Age  
Ethnicity White □             Black □             Asian  □        Caucasian □                      
Hispanic □               Other □ , Please specify:____________  
Occupation  
Smoking Status Smoker □       Non-Smoker □     How many per day ? __ 
How long? __   
Never Smoke □ 
Alcohol 
Consumption 
Yes □           How many Units per week? __ 





Medical History*:  
Are there any medical conditions to report?      Yes □           No □ 












Presenting Complaint  
History of Presenting Complaint Onset: 
Location: 





Past Dental History Previous Dental Treatments: 
 







Social History Availability for Appointments: 
Social Status: 
Number of Children:  
 
Family History Any disease running in the family 
(Including Gum Disease) 



















    
blood 
 





















Periodontal Status  
 
    Gingival Biotype 
 











              
 
    












      BPE   
   
   
 





   










Buccal Date 8 7 6 5 4 3 2 1 1 2 3 4 5 6 7 8 
Recession                  
                  
PPD                  
                  
Mobility                  
                  
Furcation                  
                  
 
Palatal Date 8 7 6 5 4 3 2 1 1 2 3 4 5 6 7 8 
Recession                  
                  
PPD                  
                  
Mobility                  
                  
Furcation                  









Lingual Date 8 7 6 5 4 3 2 1 1 2 3 4 5 6 7 8 
Recession                  
                  
PPD                  
                  
Mobility                  
                  
Furcation                  
 
Buccal Date 8 7 6 5 4 3 2 1 1 2 3 4 5 6 7 8 
Recession                  
                  
PPD                  
                  
Mobility                  
                  
Furcation                  





















































Please mark the correct answer to the following questions: 
 
1- Age  
Range 18-65 years 
 
       2-General Health 
              Good general health (smokers and diabetics will be included) 
 
       3-Previous Periodontal therapy 
            Should had no periodontal treatment/medication within the last 
               6 months 
 
      4-Consent 
Yes                  No* 
 
□                        □ 
 
 
□                □ 
 
 






         Demonstrate understanding of the study and willingness to         
participate as evidence by voluntary written informed consent and has 
received a signed and dated copy of the informed consent form. 
 
 
□                         □ 
*Note: If any of the above questions are answered “No”, the subject should be withdrawn from 
the study as a “screen failure” on the study conclusion page. 
  
 Exclusion Criteria 
Please mark the correct answers to the following questions: 
 
1-Complicated Medical History 
           Any medication that can affect gingival health 
 
2-Pergnancy 
           Women who are known to be pregnant or who are intending to 
become pregnant over the duration of the study. 
 
3-Periodontal Therapy 
           Periodontal treatment within the last 6 months &/or antimicrobial 
therapy within the last 3 months.  
 
4-Identifiable blood borne transmissible disease 
 
Yes*                      No 








□                           □ 
 
 
□                           □ 
 
*Note: If any of the above questions are answered “Yes”, the subject should be withdrawn 






Fitness and Eligibility to Participate in Study: 
In the investigator`s opinion, on the basis of the screening assessment and 
Inclusion and Exclusion criteria at this visit, is the subject eligible and fit to 
participate in the study? 
Yes      □                No      □ 
 




























Has there been any deviation from the protocol since the last visit?  Yes □      No 
□ 
If “Yes”, please record the deviation details on the comments page. 
 
Did any unwanted sign/symptoms appear or worsen since last visit? Yes □      No 
□ 
If “Yes”, please describe on the comment page. 
 
Is the subject eligible to continue in the study?   Yes □      No □ 
If “No”, please complete the study conclusion page. 
  
 
     
 
Sample Collection:  
 
Sample Type Time of Collection Tooth / Site( ≥5mm) 
Plaque (1)   
Plaque (2)   





























































Has there been any deviation from the protocol since the last visit?  Yes □      No 
□ 
If “Yes”, please record the deviation details on the comments page. 
 
Did any unwanted sign/symptoms appear or worsen since last visit? Yes □      No 
□ 
If “Yes”, please describe on the comment page. 
 
Is the subject eligible to continue in the study?   Yes □      No □ 














































Has there been any deviation from the protocol since the last visit?  Yes □      No 
□ 
If “Yes”, please record the deviation details on the comments page. 
 
Did any unwanted sign/symptoms appear or worsen since last visit? Yes □      No 
□ 
If “Yes”, please describe on the comment page. 
 
Is the subject eligible to continue in the study?   Yes □      No □ 

















    
blood 
 






Sample Type Time of Collection Tooth / Site( ≥5mm) 
Plaque (1)   
Plaque (2)   


















Periodontal Chart  































Please indicate any additional information that has not been addressed on the 
previous case report pages. 
      
Page Section Heading Comment 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   





Did the subject complete the entire study?  Yes □          No □ 
If “No” is marked, please indicate the primary reason below. Please mark only 
one. 
 
Lost to follow-up              □ 
Protocol Deviation           □ 
Withdrawal of Consent   □    Please specify:  
Adverse Event                   □    Please specify: 
Other                                  □    Please specify:   
 
 
Was there contact with the subject after the final visit?    Yes □    No □ 
If there was a contact in relation to this study, please complete the following: 
 
Method of Contact          Telephone □                   Letter □ 
                                             Other □   Please specify:  
 




I confirm that I have reviewed all the data collected in this Case Report Form 
and take responsibility that the information is accurate and complete. 
 





6.2.3 Serum ELISA Protocol 
6.2.3.1 High sensitivity CRP 
All the reagents were brought to room temperature (20-25 ͦ C) before use. Both 
the test and control samples for serum were diluted at an optimized dilution factor 
of x 1000 .50µl of standard and samples were applied into appropriate wells in 
duplicate in a 96 well plate pre-coated with antibody. The plate was incubated for 
60 minutes at room temperature before the solutions were carefully emptied by 
inverting plate and shaking contents out then dried by tapping on a thick layer of 
tissues. Approximately 350µl of wash buffer was added to each well and kept for 
20 seconds before emptying as above. The washing process was repeated for a 
total of 4 times. Then 100µl of CRP tracer was added to each well using the same 
pipetting order as applied in previous steps and again incubated for 60 minutes at 
room temperature. Washing was done as described above before 100µ of 
substrate solution was added to each well and incubated uncovered for 30 
minutes at room temperature. The reaction was stopped by adding 100µl of Stop 
Solution and the plates read immediately at 405 nm using a plate reader (Optima 
BMG LABTECH. Germany). 
 
6.2.3.2 High sensitivity IL-6 
All the reagents were brought to room temperature (20-25 ͦ C) before use. 100µl 
of Assay Diluent were added to each well in the pre-coated plate. 100µl of 
standard and samples were applied into appropriate wells in duplicate, and 
incubated for 2 hours at room temperature on microplate shaker before the 
solutions were carefully emptied by inverting plate and shaking contents out then 
dried by tapping on a thick layer of tissues at least 5 times. Approximately 400µl 
of wash buffer was added to each well and kept for 20 seconds before emptying 
as above. The washing process was repeated for a total of 6 times. Then 200µl of 
Human IL-6 HS Conjugate was added to each well using the same pipetting order 
as applied in previous steps and again incubated for 2 hours at room temperature 
on the shaker. Washing was done as described above before 50µl of substrate 
solution was added to each well and incubated for 60 minutes at room 
temperature. Without washing the plate, 50µl of Amplifier Solution was added to 
each well and incubated for 30 minutes at room temperature. The reaction was 
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stopped by adding 50µl of Stop Solution and the plates read immediately at 490 
nm using a plate reader (Optima BMG LABTECH. Germany). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
